{"meta":{"query_hash":"9ccf8b315765","filters":{"venue":"Therapeutic Advances in Medical Oncology"},"cohort_total":84,"direct_labels_cover":0,"predictions_cover":84,"exported":84,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/9ccf8b315765","api":"https://metacan.xera.ac/api/v1/cohort?venue=Therapeutic+Advances+in+Medical+Oncology"},"results":[{"id":"W2086837512","doi":"10.1177/1758834012475152","title":"Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects","year":2013,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Triple-negative breast cancer; Medicine; Breast cancer; Immunotherapy; Immune system; Cancer research; Immune checkpoint; Tumor-infiltrating lymphocytes; Estrogen receptor; Cancer; Immunology; Oncology; Internal medicine","score_opus":0.08073664781397404,"score_gpt":0.4189070756368191,"score_spread":0.33817042782284507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086837512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78971016,0.19103304,0.000051841223,0.0132084275,0.001414469,0.002051843,0.000012126721,0.00008167535,0.0024364362],"genre_scores_gemma":[0.9341289,0.0628072,0.00009406612,0.0011434156,0.00008046558,0.00064026704,0.000008901884,0.00003999268,0.0010568204],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9938403,0.0030669987,0.0011171383,0.00069104735,0.00020191798,0.0010826],"domain_scores_gemma":[0.9946838,0.0045088944,0.00020568639,0.00039771348,0.00012532924,0.000078574056],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036399532,0.00033440598,0.0009789347,0.00041882638,0.00019908063,0.000024960364,0.00065607106,0.0009670422,0.0030224072],"category_scores_gemma":[0.00034051933,0.00026094614,0.00008761198,0.00072194036,0.0037081114,0.00039469873,0.00018701467,0.002487939,0.00025140753],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031709769,0.0017265464,0.04510212,0.00003647751,0.00021441051,0.000043162876,0.0014679069,0.0000030754386,0.0026078394,0.0022359076,0.00007179344,0.9433198],"study_design_scores_gemma":[0.031712703,0.0055873296,0.77358097,0.0007788901,0.000055010267,0.0011433562,0.005386001,0.00044719796,0.0023551865,0.036041103,0.14177792,0.0011343675],"about_ca_topic_score_codex":0.00094486726,"about_ca_topic_score_gemma":0.0009223635,"teacher_disagreement_score":0.9421854,"about_ca_system_score_codex":0.00032359982,"about_ca_system_score_gemma":0.00063521176,"threshold_uncertainty_score":0.99998426},"labels":[],"label_agreement":null},{"id":"W2105738161","doi":"10.1177/1758834010374727","title":"Highlights of the 2nd European Lung Cancer Conference","year":2010,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Internal medicine","score_opus":0.015730350520810843,"score_gpt":0.41357133399359536,"score_spread":0.3978409834727845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105738161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68012226,0.018897275,0.0014582255,0.06461581,0.0052772965,0.001303406,0.000018489825,0.00007816899,0.22822908],"genre_scores_gemma":[0.9938077,0.00264184,0.00034220546,0.002406601,0.00019011114,0.000042332405,0.0000028339934,0.000012373207,0.00055404415],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895614,0.0001223522,0.00027426257,0.00016884875,0.00029104052,0.00018734687],"domain_scores_gemma":[0.9993184,0.00015835877,0.0001127131,0.00023524842,0.000068550326,0.000106686515],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000246713,0.00009821521,0.0002704939,0.000038651906,0.000044580047,0.0000021665453,0.0002097915,0.00009941253,0.0016035985],"category_scores_gemma":[0.00007086072,0.000053873526,0.00005027414,0.00015923027,0.00048122247,0.000050838196,0.000044451448,0.00041434952,0.0000051638463],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001850354,0.0006290051,0.043428726,0.00009829992,0.00015915117,0.000104290695,0.0018760035,0.000010771383,0.0037960391,0.029298503,0.00016681655,0.9202474],"study_design_scores_gemma":[0.0047841268,0.00037102908,0.092026696,0.00029189064,0.00032151482,0.000090162255,0.0001881184,0.0006066809,0.0015005053,0.002416082,0.89726305,0.00014013246],"about_ca_topic_score_codex":0.000061080755,"about_ca_topic_score_gemma":0.0010242391,"teacher_disagreement_score":0.92010725,"about_ca_system_score_codex":0.00009049444,"about_ca_system_score_gemma":0.0006660393,"threshold_uncertainty_score":0.99930906},"labels":[],"label_agreement":null},{"id":"W2111842868","doi":"10.1177/1758834011422556","title":"An overview of the c-MET signaling pathway","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":864,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Signal transduction; Hepatocyte growth factor; Receptor tyrosine kinase; Cancer research; Medicine; Tyrosine kinase; Cell biology; C-Met; Motility; Receptor; Biology; Internal medicine","score_opus":0.10909985669006583,"score_gpt":0.41079953937097025,"score_spread":0.3016996826809044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111842868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9491566,0.031728543,0.00046408369,0.00071198295,0.0010689822,0.00041972238,0.000004374221,0.00004234412,0.016403388],"genre_scores_gemma":[0.9917508,0.0015297764,0.0011377368,0.005408177,0.00011351516,0.00001899565,0.0000035120936,0.000010325403,0.000027171325],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9982824,0.0006591848,0.00036684834,0.00020662665,0.00024702906,0.00023791014],"domain_scores_gemma":[0.99908406,0.00026278623,0.00013497105,0.0003275939,0.00006003127,0.00013055009],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009384079,0.00011214484,0.000488163,0.000051463354,0.00002786423,3.8951788e-7,0.0003227105,0.00029759525,0.001117984],"category_scores_gemma":[0.00012802023,0.0000664187,0.0000696977,0.00021340363,0.00078840647,0.000072618364,0.00005801101,0.00047002282,0.000013748532],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019056874,0.0023658944,0.073717535,0.00019971664,0.000106482534,0.00043457732,0.007294893,0.000016777341,0.015504562,0.05472069,0.000019643816,0.8437135],"study_design_scores_gemma":[0.017118849,0.025820632,0.20941952,0.0011018035,0.0005373871,0.001847814,0.004330296,0.0006200117,0.04272555,0.46960452,0.2260323,0.00084133394],"about_ca_topic_score_codex":0.000013908174,"about_ca_topic_score_gemma":0.00003515853,"teacher_disagreement_score":0.8428722,"about_ca_system_score_codex":0.000048754744,"about_ca_system_score_gemma":0.00048006725,"threshold_uncertainty_score":0.99979514},"labels":[],"label_agreement":null},{"id":"W2113562909","doi":"10.1177/1758834009352498","title":"Review: Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions","year":2009,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"","keywords":"Temsirolimus; Pazopanib; Medicine; Axitinib; Sorafenib; Sunitinib; Bevacizumab; Everolimus; Renal cell carcinoma; Targeted therapy; Oncology; PI3K/AKT/mTOR pathway; Adjuvant; Clinical trial; Vascular endothelial growth factor; Adjuvant therapy; Internal medicine; Pharmacology; Discovery and development of mTOR inhibitors; Cancer; VEGF receptors; Chemotherapy","score_opus":0.03495072061428077,"score_gpt":0.38143006076980135,"score_spread":0.34647934015552057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113562909","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048249785,0.93272614,0.0004165066,0.014833281,0.00047603235,0.002073356,0.000009851354,0.000048591926,0.001166447],"genre_scores_gemma":[0.23545934,0.7554459,0.0020378649,0.0058571375,0.0005207596,0.0004963389,0.00006630509,0.000022734106,0.000093629365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980205,0.00025240012,0.0005392663,0.00046802722,0.0002810715,0.00043869915],"domain_scores_gemma":[0.9987644,0.0003986682,0.00015240008,0.00028095688,0.00007590589,0.0003276781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039980907,0.00032137026,0.0009271504,0.00013323611,0.00008278635,0.0000044828616,0.0001051048,0.00012938406,0.0002158931],"category_scores_gemma":[0.00004022072,0.00020762667,0.00017043494,0.00025950762,0.00017574812,0.00007492522,0.000012068573,0.0002999002,0.000005924683],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075539644,0.0017648194,0.00048554176,0.0002227579,0.000047952937,0.00009312064,0.00025786672,6.9091624e-7,0.00026107492,0.00015980659,0.00024987274,0.9957011],"study_design_scores_gemma":[0.008948921,0.010303712,0.006513787,0.00022666957,0.000338051,0.00022961682,0.00008302756,0.00009129778,0.00084870344,0.0012235529,0.97100556,0.00018710464],"about_ca_topic_score_codex":0.000007846477,"about_ca_topic_score_gemma":0.000024421583,"teacher_disagreement_score":0.995514,"about_ca_system_score_codex":0.0004986499,"about_ca_system_score_gemma":0.00042599608,"threshold_uncertainty_score":0.846677},"labels":[],"label_agreement":null},{"id":"W2118364274","doi":"10.1177/1758834012438214","title":"Exemestane in the prevention setting","year":2012,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Exemestane; Medicine; Breast cancer; Aromatase; Oncology; Adjuvant; Internal medicine; Clinical trial; Cancer; Gynecology","score_opus":0.010534767533464436,"score_gpt":0.35654649660876714,"score_spread":0.3460117290753027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118364274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9028655,0.082256384,0.0016612759,0.0018411285,0.00052849925,0.00037201858,4.4948e-7,0.000011254152,0.010463473],"genre_scores_gemma":[0.9910029,0.00644455,0.00038898832,0.0017450681,0.0002787028,0.000051837327,0.000015762387,0.000009000251,0.000063183055],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863917,0.0004953881,0.00021383962,0.00014039161,0.00017763,0.00033361223],"domain_scores_gemma":[0.9996002,0.00012707451,0.000057968075,0.00014411531,0.0000085812635,0.00006205932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014222325,0.00009251511,0.00013235709,0.000025914629,0.000030250054,0.0000025577704,0.00021460041,0.00027764405,0.000042391664],"category_scores_gemma":[0.00011783922,0.000060137525,0.00003903574,0.00012270299,0.00013622308,0.000008660264,0.000042133266,0.0003285195,0.000010998103],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021219967,0.0006025511,0.013777598,0.000019439784,0.000023108762,0.00004312544,0.0006205588,0.000025070189,0.010725789,0.0018743505,0.00009692174,0.97197926],"study_design_scores_gemma":[0.0034847225,0.0019243725,0.010734532,0.00009860967,0.00003926244,0.00049052027,0.0014639853,0.00030010805,0.0066760844,0.003885347,0.97054183,0.00036060665],"about_ca_topic_score_codex":0.0000022383988,"about_ca_topic_score_gemma":0.000026004574,"teacher_disagreement_score":0.97161865,"about_ca_system_score_codex":0.000029422046,"about_ca_system_score_gemma":0.00008401355,"threshold_uncertainty_score":0.2452337},"labels":[],"label_agreement":null},{"id":"W2122895515","doi":"10.1177/1758834011422557","title":"c-MET as a potential therapeutic target and biomarker in cancer","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Hepatocyte growth factor; C-Met; Cancer research; Receptor tyrosine kinase; Cabozantinib; Angiogenesis; Tyrosine kinase; Cancer; Targeted therapy; Oncology; Internal medicine; Receptor; VEGF receptors","score_opus":0.042716451349543764,"score_gpt":0.38644154722704865,"score_spread":0.3437250958775049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122895515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89663017,0.077722676,0.00088259974,0.005008004,0.0014301392,0.00074148865,0.000005648673,0.00007469294,0.017504567],"genre_scores_gemma":[0.97606725,0.011408451,0.00091104355,0.011281975,0.00010204709,0.000109504246,0.000007101373,0.000019969135,0.00009268531],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979886,0.00047163726,0.00041785423,0.0004209419,0.00021530577,0.0004856673],"domain_scores_gemma":[0.9992244,0.0002675411,0.00009619953,0.00019994614,0.000021947004,0.00018991677],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006438827,0.0002055199,0.0006518933,0.00020040452,0.000038211794,0.0000015686624,0.00017924147,0.00052095734,0.0035715068],"category_scores_gemma":[0.00006634969,0.00015664904,0.000053969314,0.00025428142,0.0009996839,0.00010983634,0.00007899526,0.00067078834,0.000033606204],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00428738,0.0012536944,0.112044714,0.00008637978,0.0001418846,0.0025474979,0.002794667,0.0000033064598,0.0038653233,0.006241722,0.000019496536,0.86671394],"study_design_scores_gemma":[0.013787662,0.0056364173,0.7510293,0.00023308098,0.00021849826,0.0019347129,0.0011075162,0.00095816294,0.00062959804,0.13463078,0.08928251,0.0005517461],"about_ca_topic_score_codex":0.00014428636,"about_ca_topic_score_gemma":0.00018471872,"teacher_disagreement_score":0.8661622,"about_ca_system_score_codex":0.00009821907,"about_ca_system_score_gemma":0.00038371288,"threshold_uncertainty_score":0.99733937},"labels":[],"label_agreement":null},{"id":"W2139562398","doi":"10.1177/1758834010395342","title":"Health-related quality of life and cancer clinical trials","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Clinical trial; Cancer; Quality of life (healthcare); Quality (philosophy); Intensive care medicine; Oncology; Internal medicine; Nursing","score_opus":0.299585135842967,"score_gpt":0.554391340122369,"score_spread":0.25480620427940204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139562398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66893727,0.2957457,0.0012334372,0.019657295,0.0035007233,0.0009642637,0.000017480761,0.00007021348,0.009873592],"genre_scores_gemma":[0.92871773,0.06162009,0.00023267133,0.00911276,0.00018922972,0.00004906674,0.0000037858504,0.000013299506,0.00006136441],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99395823,0.0027542545,0.002307749,0.0003036473,0.00039071153,0.00028537482],"domain_scores_gemma":[0.99593467,0.0026190977,0.0006827488,0.00022277415,0.00007096863,0.00046976193],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012072578,0.00013481492,0.0020359056,0.00007900237,0.000022921775,9.792931e-7,0.00013159028,0.00038800493,0.0019610357],"category_scores_gemma":[0.0025507482,0.00009802461,0.00014421213,0.00020887362,0.0008103953,0.00005280556,0.00004739355,0.0006178388,0.0000038356943],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025671138,0.000386682,0.13425015,0.00016587747,0.00009942108,0.00001612295,0.0016360332,1.8011073e-7,0.000008263589,0.0024325515,0.000038904735,0.8583987],"study_design_scores_gemma":[0.029229771,0.007518109,0.638817,0.0008397858,0.0002549613,0.00008858007,0.0041224724,0.00021454727,0.000079700694,0.024404883,0.29389945,0.00053074706],"about_ca_topic_score_codex":0.0021196327,"about_ca_topic_score_gemma":0.0059261993,"teacher_disagreement_score":0.85786796,"about_ca_system_score_codex":0.00010143913,"about_ca_system_score_gemma":0.0013784664,"threshold_uncertainty_score":0.9989513},"labels":[],"label_agreement":null},{"id":"W2156077273","doi":"10.1177/1758834009358417","title":"Renal cell carcinoma bone metastases: clinical advances","year":2010,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Zoledronic acid; Oncology; Systemic therapy; Targeted therapy; Bone disease; Clinical trial; Kidney cancer; Internal medicine; Cancer; Breast cancer; Osteoporosis","score_opus":0.04202467694925865,"score_gpt":0.4341992174272958,"score_spread":0.3921745404780371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156077273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7164997,0.15798834,0.0066073304,0.033127263,0.008227886,0.0010237372,0.000016860806,0.0002858823,0.07622304],"genre_scores_gemma":[0.9570547,0.013293394,0.010140672,0.017508544,0.0012974739,0.00009505071,0.000022649187,0.000035325596,0.0005522289],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961675,0.0005966003,0.0011331296,0.00065529125,0.0007302365,0.0007172469],"domain_scores_gemma":[0.99623567,0.0022751205,0.00024634058,0.00048266092,0.000104122155,0.0006560982],"candidate_categories":["sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032751402,0.00030681418,0.0012984513,0.00016826506,0.00010583791,0.00000501936,0.00033242267,0.0005774294,0.0016387999],"category_scores_gemma":[0.0018570002,0.0002194017,0.00019802935,0.0003133199,0.0028310397,0.00015007505,0.00013592304,0.002849379,0.00012739636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060144614,0.0013678863,0.099375844,0.000112147376,0.00004282843,0.0030519716,0.0002537215,9.912364e-7,0.00082600536,0.0008057081,0.00069837813,0.8928631],"study_design_scores_gemma":[0.006852282,0.0025094417,0.015878886,0.00007331657,0.00020963803,0.0011096569,0.0003774995,0.00018755489,0.00043319882,0.0033297972,0.9687591,0.0002795864],"about_ca_topic_score_codex":0.000010609767,"about_ca_topic_score_gemma":0.00020785004,"teacher_disagreement_score":0.9680608,"about_ca_system_score_codex":0.00005429875,"about_ca_system_score_gemma":0.000643067,"threshold_uncertainty_score":0.9998827},"labels":[],"label_agreement":null},{"id":"W2166720958","doi":"10.1177/1758834011399306","title":"Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; Lung cancer; Regimen; Oncology; Maintenance therapy; Intensive care medicine; Chemotherapy; Immunotherapy; Disease; Internal medicine; Clinical trial; Cancer; Adverse effect","score_opus":0.018753666172804957,"score_gpt":0.3790955163536733,"score_spread":0.36034185018086834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166720958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93918973,0.041086216,0.002474214,0.0030665898,0.0005660006,0.001276862,0.0000064904716,0.000048757916,0.012285124],"genre_scores_gemma":[0.9688655,0.025221707,0.002273026,0.0028602947,0.00004714405,0.00048662673,0.000004570964,0.00002163887,0.00021947414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820334,0.0001213979,0.00053052424,0.00044992534,0.00024074076,0.00045407997],"domain_scores_gemma":[0.9990858,0.00024336876,0.00013273036,0.00025939714,0.00007331492,0.00020543428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004014038,0.00022538131,0.00068755477,0.00012859325,0.000050169263,0.0000028438822,0.0001513951,0.0002103821,0.00043213982],"category_scores_gemma":[0.00006707959,0.00016143854,0.000059395676,0.000272733,0.00034154844,0.0001695422,0.0000385928,0.00040791545,0.000003668282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045918176,0.0007867748,0.66592306,0.000065077,0.00004151719,0.0000872191,0.0021514434,0.000012426952,0.000046193763,0.00054016686,0.0000068758973,0.32988006],"study_design_scores_gemma":[0.01459488,0.0013119807,0.960745,0.00023985749,0.00008734517,0.00003313498,0.0010856995,0.0007739674,0.00014262361,0.004340821,0.016394632,0.00025005528],"about_ca_topic_score_codex":0.00047669705,"about_ca_topic_score_gemma":0.0016313792,"teacher_disagreement_score":0.32963002,"about_ca_system_score_codex":0.00075115386,"about_ca_system_score_gemma":0.0007881748,"threshold_uncertainty_score":0.6583273},"labels":[],"label_agreement":null},{"id":"W2610105293","doi":"10.1177/1758834017704329","title":"Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical Practice; Affect (linguistics); Lung cancer; Medical physics; Oncology; Intensive care medicine; Family medicine; Psychology","score_opus":0.31719594479789304,"score_gpt":0.5822947835792166,"score_spread":0.26509883878132356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610105293","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000109721455,0.9923521,0.00041448761,0.0009995875,0.00024947166,0.0055158352,0.000046078047,0.000004320347,0.00030836085],"genre_scores_gemma":[0.00014508322,0.98440075,0.013844258,0.0008429075,0.000049687445,0.0006328195,0.000020132433,0.000026487407,0.000037889713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691874,0.00068386085,0.0014922288,0.00038595806,0.00030056495,0.00021864646],"domain_scores_gemma":[0.9888418,0.008171008,0.0020915768,0.0005594831,0.00021691894,0.00011924681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017282215,0.00025596388,0.0026136613,0.00007176803,0.000029894552,0.0000030371846,0.00028692835,0.00034232592,0.00002185922],"category_scores_gemma":[0.0067777224,0.00015372114,0.00032644268,0.00028151344,0.0005500702,0.00011006113,0.00009847686,0.00052517763,1.3518577e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004064393,0.0004403649,0.0040198844,0.14587545,0.00019376786,0.000010007616,0.000085430096,0.000004348942,2.82273e-7,0.00007086736,0.00002161973,0.8492373],"study_design_scores_gemma":[0.0019679207,0.0006562028,0.0007076293,0.20157343,0.005921803,0.00003743577,0.000014997073,0.00006481096,0.000002897317,0.00024435442,0.78868735,0.000121158824],"about_ca_topic_score_codex":0.00019446334,"about_ca_topic_score_gemma":0.00019660234,"teacher_disagreement_score":0.84911615,"about_ca_system_score_codex":0.00024850166,"about_ca_system_score_gemma":0.00472752,"threshold_uncertainty_score":0.83864176},"labels":[],"label_agreement":null},{"id":"W2787639107","doi":"10.1177/1758834017753338","title":"Turning <i>EGFR</i> mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors","year":2018,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Osimertinib; Afatinib; Erlotinib; T790M; Gefitinib; Medicine; Lung cancer; Tolerability; Oncology; Epidermal growth factor receptor; Resistance mutation; Erlotinib Hydrochloride; Tyrosine kinase; Internal medicine; Cancer research; Cancer; Adverse effect; Biology; Receptor","score_opus":0.018763228355649305,"score_gpt":0.4154327985471971,"score_spread":0.3966695701915478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787639107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047978314,0.990311,0.0030115563,0.00085373956,0.0011172176,0.0031267742,0.000058732596,0.00008082088,0.0009603242],"genre_scores_gemma":[0.0016503732,0.9901529,0.0012753842,0.001326833,0.0020520824,0.0023716923,0.00058194343,0.00015982552,0.00042895955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959675,0.00041489178,0.0010355159,0.0010164514,0.00078080414,0.0007848272],"domain_scores_gemma":[0.997436,0.00056613825,0.0006824233,0.00045828844,0.00022148885,0.0006356897],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039212094,0.00082202203,0.0022336852,0.00033186466,0.00021129537,0.000029511828,0.00037350552,0.00060698745,0.00074504875],"category_scores_gemma":[0.0000447819,0.0005453292,0.00035453352,0.00073641,0.0008890207,0.00020571436,0.000095029194,0.0011587486,0.000027888264],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007131051,0.000882659,0.00012475868,0.0057703736,0.0009787729,0.001742103,0.0010866256,0.00009645279,0.00000548786,0.000043901317,0.00011241551,0.9884433],"study_design_scores_gemma":[0.008598335,0.0032202962,0.000035999063,0.02319677,0.004572718,0.0002084699,0.00013881136,0.0005323614,0.000035582532,0.000058409147,0.9587455,0.0006567627],"about_ca_topic_score_codex":0.00018117414,"about_ca_topic_score_gemma":0.00039147827,"teacher_disagreement_score":0.9877866,"about_ca_system_score_codex":0.004168615,"about_ca_system_score_gemma":0.011225608,"threshold_uncertainty_score":0.99969983},"labels":[],"label_agreement":null},{"id":"W2945349403","doi":"10.1177/1758835919850367","title":"Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine <i>versus</i> FOLFIRINOX in advanced pancreatic cancer: a systematic review","year":2019,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services","funders":"Celgene","keywords":"FOLFIRINOX; Medicine; Gemcitabine; Irinotecan; Internal medicine; Oxaliplatin; Neutropenia; Oncology; Pancreatic cancer; Gastroenterology; Cancer; Chemotherapy; Colorectal cancer","score_opus":0.11378650241791426,"score_gpt":0.5148520294269145,"score_spread":0.4010655270090003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945349403","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022723131,0.9747282,0.000078455945,0.0001986218,0.00071784627,0.01397448,0.00004002471,0.00004786048,0.0099872425],"genre_scores_gemma":[0.0005258025,0.9913079,0.00036349244,0.00039596378,0.00011372648,0.0065215323,0.00012465667,0.000095932905,0.0005509585],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9858143,0.0065593435,0.0038015721,0.0011547706,0.0014966466,0.0011733853],"domain_scores_gemma":[0.9744994,0.021839203,0.0017231778,0.0012014566,0.00028739107,0.0004493847],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006233881,0.0010157105,0.022589322,0.00093682326,0.00004922141,0.0000056200056,0.0009905145,0.0010041835,0.0005371016],"category_scores_gemma":[0.001905364,0.0007104807,0.0007490254,0.0023160335,0.0011141717,0.0001775085,0.00026379162,0.0024405257,0.00010178952],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0021519451,0.0006866721,0.00045926703,0.8441633,0.0010861235,0.00038113882,0.00015398688,0.0000048553206,9.868287e-7,0.00086016516,0.000016957547,0.1500346],"study_design_scores_gemma":[0.011095159,0.0027168537,0.00016104095,0.8574945,0.0094208345,0.00014193116,0.00015512423,0.00015630576,0.0000011391757,0.00021669477,0.11786878,0.0005716743],"about_ca_topic_score_codex":0.0003012265,"about_ca_topic_score_gemma":0.0014550668,"teacher_disagreement_score":0.14946294,"about_ca_system_score_codex":0.0043957196,"about_ca_system_score_gemma":0.008114756,"threshold_uncertainty_score":0.9998609},"labels":[],"label_agreement":null},{"id":"W2945903793","doi":"10.1177/1758835919846372","title":"FAM84B promotes prostate tumorigenesis through a network alteration","year":2019,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"Cancer Research Society","keywords":"DU145; Cancer research; Carcinogenesis; Prostate cancer; Cell growth; Biology; Metastasis; Cell cycle; Cell; Cancer; Medicine; Genetics; LNCaP","score_opus":0.02679852681546533,"score_gpt":0.39975956751888975,"score_spread":0.3729610407034244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945903793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8429811,0.082782604,0.003080984,0.026072886,0.0024441285,0.00489608,0.000007141369,0.0002329946,0.03750209],"genre_scores_gemma":[0.9707373,0.019634688,0.0021023825,0.00435656,0.000582279,0.00030424344,0.000058933376,0.00003767611,0.002185965],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783754,0.00021088062,0.00039686332,0.00038571583,0.0005774491,0.00059154775],"domain_scores_gemma":[0.9990945,0.0003335501,0.00009155299,0.00024665365,0.00007160975,0.00016214087],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060892745,0.00018129707,0.00053576165,0.000063570726,0.000056956193,0.000008677103,0.00015095029,0.0001988952,0.0012984517],"category_scores_gemma":[0.00006531684,0.00012415017,0.00006456911,0.00037910402,0.0002606335,0.0002081473,0.000055413,0.00044702666,0.00017798026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038304823,0.0010459992,0.09870948,0.0003551605,0.00015924819,0.00072691386,0.0019695729,0.00016164433,0.0010063295,0.0043825065,0.00023117168,0.8874215],"study_design_scores_gemma":[0.018060667,0.008863603,0.016480006,0.00086045003,0.00012431333,0.00035639055,0.00068501366,0.004914311,0.0030763454,0.044168737,0.9018919,0.00051830563],"about_ca_topic_score_codex":0.000018329907,"about_ca_topic_score_gemma":0.000046517802,"teacher_disagreement_score":0.9016607,"about_ca_system_score_codex":0.00033458386,"about_ca_system_score_gemma":0.0006944732,"threshold_uncertainty_score":0.9996145},"labels":[],"label_agreement":null},{"id":"W3001249325","doi":"10.1177/1758835919895756","title":"Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Anaplastic lymphoma kinase; Cancer research; ROS1; Epidermal growth factor receptor; Medicine; Mutation; Lung cancer; Anaplastic large-cell lymphoma; PI3K/AKT/mTOR pathway; ERBB3; Fusion gene; Protein kinase domain; Cancer; Lymphoma; Biology; Gene; Oncology; Signal transduction; Adenocarcinoma; Genetics; Immunology; Internal medicine","score_opus":0.01754185532272969,"score_gpt":0.38092515561861406,"score_spread":0.3633833002958844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001249325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009568461,0.99112487,0.0037830186,0.0007532045,0.0008549815,0.0017994721,0.00005899177,0.000060177288,0.0006084636],"genre_scores_gemma":[0.005955652,0.9899852,0.0012930114,0.0011517449,0.00050044415,0.0005395826,0.00043518326,0.00007784426,0.00006128781],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99693435,0.0003506556,0.0009862294,0.0007368574,0.0005004109,0.00049146434],"domain_scores_gemma":[0.9975937,0.0011302744,0.00057938905,0.00015876199,0.00010998387,0.0004278847],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023352163,0.0005333476,0.001991994,0.00027023343,0.00013591805,0.00001613246,0.00017399946,0.00061492884,0.00034105737],"category_scores_gemma":[0.00022108686,0.00040676497,0.00018181774,0.00045529468,0.0002533121,0.00017385188,0.00008754366,0.0005856515,0.000016862883],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011694284,0.0002662014,0.00023682941,0.007146043,0.00022082076,0.002088942,0.0010903376,0.00001240888,0.0000032306546,0.00007794573,0.000032886015,0.9887074],"study_design_scores_gemma":[0.0072484165,0.0015646714,0.00033548527,0.0067930543,0.0042642304,0.0004991841,0.0003843027,0.0038251241,0.000009400781,0.00027735365,0.9741959,0.0006028795],"about_ca_topic_score_codex":0.000079232486,"about_ca_topic_score_gemma":0.00009050827,"teacher_disagreement_score":0.9881045,"about_ca_system_score_codex":0.0013057769,"about_ca_system_score_gemma":0.0024724677,"threshold_uncertainty_score":0.9998384},"labels":[],"label_agreement":null},{"id":"W3009738710","doi":"10.1177/1758835920915299","title":"Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Servier; Ipsen Fund; NuCana","keywords":"Medicine; Internal medicine; Everolimus; Progression-free survival; Oncology; Prospective cohort study; Sample size determination; Chemotherapy","score_opus":0.05922102353235283,"score_gpt":0.4006608372262131,"score_spread":0.3414398136938603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009738710","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011125445,0.9883556,0.000022728258,0.0013854626,0.00006090869,0.009717175,0.000107442385,0.00007112848,0.00016830978],"genre_scores_gemma":[0.003680539,0.9896366,0.00019086183,0.0021346274,0.000036068508,0.0035788282,0.0003378125,0.00013293384,0.0002717443],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9908424,0.0025133125,0.0026896186,0.0015945315,0.0013009652,0.0010591828],"domain_scores_gemma":[0.99521106,0.0018211422,0.0010486945,0.0009904357,0.00013416434,0.00079450116],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003606937,0.0012947835,0.018935809,0.00094777637,0.0000522766,0.0000152303455,0.0006022308,0.00009457268,0.0013275804],"category_scores_gemma":[0.00055459864,0.00072401983,0.0012424212,0.0025079856,0.0004880579,0.00022468143,0.00022002324,0.0016575193,0.000020361873],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000667627,0.0026084953,0.00036382882,0.6759689,0.03168449,0.031159492,0.000025963629,0.0000020169978,1.1047786e-7,0.00002573072,0.0000032061985,0.25749016],"study_design_scores_gemma":[0.0062262616,0.008947062,0.00021602644,0.021737061,0.71655774,0.0025292714,0.000028772207,0.000051048006,8.147788e-7,0.000051681465,0.2427687,0.0008855685],"about_ca_topic_score_codex":0.000014749652,"about_ca_topic_score_gemma":0.0002930028,"teacher_disagreement_score":0.6848732,"about_ca_system_score_codex":0.0007347482,"about_ca_system_score_gemma":0.000816455,"threshold_uncertainty_score":0.9999804},"labels":[],"label_agreement":null},{"id":"W3010740851","doi":"10.1177/1758835920909091","title":"Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Mount Sinai Hospital; Dr. H. Bliss Murphy Cancer Centre; BC Cancer Agency","funders":"","keywords":"Atezolizumab; Medicine; Metastatic breast cancer; Pembrolizumab; Oncology; Internal medicine; Hazard ratio; Triple-negative breast cancer; Breast cancer; Population; Chemotherapy; Placebo; Progression-free survival; Clinical trial; Cancer; Immunotherapy; Confidence interval; Pathology","score_opus":0.026929382798199477,"score_gpt":0.4086304143515668,"score_spread":0.3817010315533673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010740851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010003255,0.9958026,0.000020172683,0.0012542744,0.0005337702,0.0020046167,0.00007969148,0.000020624468,0.00018422588],"genre_scores_gemma":[0.002564153,0.9960965,0.00025277297,0.00020247957,0.00020516143,0.0005865021,0.00003246878,0.00005254876,0.000007436124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99562716,0.00074389146,0.0019742178,0.0005993851,0.00058390433,0.00047145432],"domain_scores_gemma":[0.9975925,0.0009225386,0.0009650858,0.00021490987,0.00009021763,0.00021476079],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010462955,0.00051520823,0.0036081194,0.00037849526,0.000031050724,0.00000682104,0.00026602007,0.00037538176,0.00038920037],"category_scores_gemma":[0.00021016612,0.00036886777,0.00039262619,0.00093983446,0.0012128715,0.00013226492,0.0001303531,0.0014196484,0.000002683095],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015037603,0.0005208394,0.0002053587,0.0065171015,0.00045096435,0.00014512993,0.0010738518,1.3169404e-7,0.000009561583,0.000039232455,0.0000033360607,0.98953074],"study_design_scores_gemma":[0.008233334,0.0015488622,0.001305107,0.06308019,0.0012730013,0.00061813724,0.0009503334,0.00015776312,0.000040916013,0.00068055885,0.9215772,0.0005345956],"about_ca_topic_score_codex":0.00017213894,"about_ca_topic_score_gemma":0.00021066981,"teacher_disagreement_score":0.98899615,"about_ca_system_score_codex":0.0010301492,"about_ca_system_score_gemma":0.0024281747,"threshold_uncertainty_score":0.9998763},"labels":[],"label_agreement":null},{"id":"W3011081636","doi":"10.1177/1758835920911229","title":"Widespread expression of Sonic hedgehog (Shh) and Nrf2 in patients treated with cisplatin predicts outcome in resected tumors and are potential therapeutic targets for HPV-negative head and neck cancer","year":2020,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; McGill University","funders":"","keywords":"Sonic hedgehog; Medicine; Cyclopamine; Cancer research; Clonogenic assay; Hedgehog; Cisplatin; Context (archaeology); Vismodegib; Cancer; Oncology; Head and neck squamous-cell carcinoma; Hedgehog signaling pathway; Head and neck cancer; Internal medicine; Chemotherapy; Cell; Biology; Signal transduction; Basal cell carcinoma","score_opus":0.02253777044378503,"score_gpt":0.33128670254536735,"score_spread":0.30874893210158233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011081636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98007685,0.018261362,0.00038362562,0.0005030118,0.000053871903,0.00066047424,0.0000308467,0.00000812144,0.000021842714],"genre_scores_gemma":[0.99589884,0.0027582094,0.00042492835,0.0006767644,0.000051179555,0.00013985713,0.000021668828,0.0000236357,0.00000492054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825686,0.00026062783,0.0004751186,0.00044982013,0.00019950893,0.0003580804],"domain_scores_gemma":[0.9992266,0.00025468288,0.00020591126,0.00010071825,0.00006725224,0.00014478239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002758647,0.00022707605,0.0005923352,0.00007979889,0.00004099367,0.000004225816,0.00011484485,0.00024916616,0.000008587917],"category_scores_gemma":[0.00040053957,0.00017362899,0.000022562317,0.00016703639,0.0004894989,0.000018268234,0.000113433685,0.00024375548,8.0537646e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004729942,0.00028276225,0.9290184,0.00024388837,0.000056971116,0.000020882444,0.0017188684,0.00012089216,0.015694635,0.000010562794,0.000006541291,0.04809565],"study_design_scores_gemma":[0.020239,0.0074660145,0.9404462,0.0007309411,0.00006072963,0.00000892938,0.0012393409,0.0017460074,0.026326394,0.0003621609,0.00092170795,0.000452592],"about_ca_topic_score_codex":0.000038994054,"about_ca_topic_score_gemma":0.00061730907,"teacher_disagreement_score":0.047643058,"about_ca_system_score_codex":0.000046397003,"about_ca_system_score_gemma":0.000111062305,"threshold_uncertainty_score":0.70803845},"labels":[],"label_agreement":null},{"id":"W3129833506","doi":"10.1177/1758835921992987","title":"Elevated risk of colorectal, liver, and pancreatic cancers among HCV, HBV and/or HIV (co)infected individuals in a population based cohort in Canada","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University; Vancouver General Hospital; University of Waterloo; BC Centre for Disease Control; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Medicine; Internal medicine; Hepatitis C virus; Pancreatic cancer; Colorectal cancer; Gastroenterology; Population; Cohort; Hazard ratio; Liver cancer; Hepatitis B virus; Hepatitis C; Cancer; Hepatitis B; Confidence interval; Immunology; Virus","score_opus":0.015118668587111741,"score_gpt":0.31980979425488204,"score_spread":0.3046911256677703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129833506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918237,0.0067696916,0.000034996367,0.00042557786,0.00009373158,0.0005763071,0.000028620898,0.000012870396,0.00023455116],"genre_scores_gemma":[0.97477347,0.02380951,0.000418211,0.0007850658,0.000017761164,0.000118988486,0.000051891177,0.00001505099,0.000010032217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975594,0.00066799874,0.0006678156,0.00033556792,0.00042075527,0.00034842084],"domain_scores_gemma":[0.9976253,0.0018279782,0.00020878285,0.00012771576,0.00006418069,0.00014603452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070192426,0.00017704147,0.0009584893,0.0001852541,0.000032583794,0.0000024484862,0.00006541457,0.0001907595,0.00029535254],"category_scores_gemma":[0.0016763977,0.00014812146,0.000019689534,0.00057778053,0.00032325802,0.0000746261,0.00004529249,0.00047482215,5.050523e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037937195,0.00012298666,0.9564727,0.0001364178,0.00007543405,0.00057507266,0.00037043015,0.00006551779,0.00004219684,0.000014240315,0.000010950144,0.04173469],"study_design_scores_gemma":[0.004263219,0.000409207,0.9864952,0.0004544675,0.00010764912,0.000023403998,0.0002737486,0.006722022,0.00011998391,0.00010819702,0.0008897262,0.00013316811],"about_ca_topic_score_codex":0.66039884,"about_ca_topic_score_gemma":0.9904844,"teacher_disagreement_score":0.33008558,"about_ca_system_score_codex":0.0014650475,"about_ca_system_score_gemma":0.0033004237,"threshold_uncertainty_score":0.6040218},"labels":[],"label_agreement":null},{"id":"W3139304883","doi":"10.1177/1758835921998586","title":"Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Myovant Sciences","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Adverse effect; Testosterone (patch); Management of prostate cancer; Internal medicine; Oncology; Gonadotropin-releasing hormone; Androgen; Androgen suppression; Cancer; Luteinizing hormone; Endocrinology; Hormone","score_opus":0.0585975078822475,"score_gpt":0.45452544383896826,"score_spread":0.39592793595672077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139304883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003756005,0.9926577,0.00056949665,0.00037710342,0.00021484429,0.0054189735,0.0000913971,0.000022307366,0.00027257754],"genre_scores_gemma":[0.000093394265,0.9918833,0.002898432,0.00029336804,0.00007443004,0.003824704,0.0006298564,0.000075164244,0.00022738849],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99716437,0.00013682494,0.0008254837,0.00061029475,0.0007511342,0.00051190023],"domain_scores_gemma":[0.99833786,0.00039560505,0.00046520235,0.00036539114,0.00026291402,0.00017301334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040257585,0.0003976905,0.002211435,0.00020646404,0.000044887183,0.0000048136603,0.00025363397,0.00036890805,0.00015502221],"category_scores_gemma":[0.000032143693,0.00024117733,0.00022293904,0.00061416964,0.00033182368,0.000092211805,0.00007442054,0.00046428925,0.0000013717215],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022893087,0.0013616557,0.0004965016,0.0104878135,0.0008947979,0.00006989729,0.000087139684,0.0000044894923,3.782742e-7,0.0002852547,0.00001370836,0.984009],"study_design_scores_gemma":[0.0151104685,0.0021478296,0.00016802161,0.016404042,0.00058468734,0.00001107773,0.00006208831,0.000011549306,0.000009913665,0.000113622766,0.9651487,0.00022804136],"about_ca_topic_score_codex":0.000004524391,"about_ca_topic_score_gemma":0.000014572461,"teacher_disagreement_score":0.98378104,"about_ca_system_score_codex":0.00064989814,"about_ca_system_score_gemma":0.0015689244,"threshold_uncertainty_score":0.9834926},"labels":[],"label_agreement":null},{"id":"W3152514714","doi":"10.1177/17588359211010156","title":"Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Jubilee Hospital; Spinal Cord Injury BC","funders":"","keywords":"Pembrolizumab; Medicine; Adenocarcinoma; Pancreas; Lung cancer; Tumor microenvironment; Lung; Gemcitabine; Pathology; Pancreatic cancer; Chemotherapy; Immune system; Oncology; Immunotherapy; Cancer research; Internal medicine; Cancer; Immunology","score_opus":0.01879562548514577,"score_gpt":0.29419115280817876,"score_spread":0.27539552732303296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152514714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856213,0.010640838,0.0006519458,0.002238259,0.000056126555,0.00063994265,0.000008447473,0.000004427077,0.00013875648],"genre_scores_gemma":[0.9949389,0.0040634647,0.00017394518,0.00068337435,0.000016871842,0.000060502865,0.0000210758,0.000016358243,0.000025525993],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978336,0.0004543529,0.0007180816,0.00022032193,0.00056149816,0.00021211918],"domain_scores_gemma":[0.9986651,0.0003782901,0.00049569085,0.00036066087,0.00006357418,0.000036670186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048320595,0.00016793433,0.00065986,0.00008114916,0.0000297362,0.000002190235,0.0002388884,0.00007278916,0.000174908],"category_scores_gemma":[0.000051564988,0.00008225629,0.00008195619,0.00057156064,0.0007205565,0.00006117327,0.000038002043,0.00023574839,2.04575e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050316095,0.0066921767,0.36567497,0.0018497037,0.0007718084,0.000758706,0.005732259,0.00015909305,0.43453625,0.00022334131,0.0000031288832,0.13328247],"study_design_scores_gemma":[0.018612422,0.0057742177,0.8487427,0.0023398092,0.00052612164,0.00086755626,0.001522513,0.0004317449,0.11817517,0.00006606024,0.0027548154,0.00018682577],"about_ca_topic_score_codex":0.00011401646,"about_ca_topic_score_gemma":0.00063616177,"teacher_disagreement_score":0.48306775,"about_ca_system_score_codex":0.00019842271,"about_ca_system_score_gemma":0.00051538204,"threshold_uncertainty_score":0.3354314},"labels":[],"label_agreement":null},{"id":"W3172779990","doi":"10.1177/17588359211019675","title":"Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health; Queen's University; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Karl Landsteiner Privatuniversität für Gesundheitswissenschaften","keywords":"Medicine; Internal medicine; Brain metastasis; Lung cancer; Oncology; Adverse effect; Retrospective cohort study; Confidence interval; Population; Fusion gene; Cancer; Metastasis; Gene","score_opus":0.01930944574526549,"score_gpt":0.44439614040856573,"score_spread":0.42508669466330024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172779990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98561686,0.0045487313,0.0003696743,0.00089958997,0.00020407204,0.0011720295,0.00007267502,0.000034370907,0.007081989],"genre_scores_gemma":[0.98858976,0.007589452,0.0012928932,0.0013102597,0.000054094085,0.0005891241,0.00046499382,0.000022662194,0.000086780536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977747,0.0002722831,0.00061154144,0.00053681585,0.00044250741,0.00036215453],"domain_scores_gemma":[0.9987292,0.00023869539,0.0002387978,0.00029173004,0.00034243928,0.00015913355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019799599,0.00021535487,0.0009827344,0.00024233959,0.000048970458,0.000008207877,0.0001854636,0.00025909618,0.00084450823],"category_scores_gemma":[0.00007903297,0.00016954103,0.00012303851,0.0021693995,0.000228457,0.000269951,0.00007014615,0.00037733707,8.736714e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044938482,0.005231598,0.7997174,0.00007438366,0.0008798231,0.00021256437,0.0054349094,0.00010141771,0.00006918192,0.00009568971,0.000006995213,0.1877266],"study_design_scores_gemma":[0.008995027,0.002088816,0.9754816,0.0003004055,0.0031560005,0.0000047939707,0.0010731074,0.0053454232,0.000876024,0.00029284006,0.0021648363,0.00022112469],"about_ca_topic_score_codex":0.00066421385,"about_ca_topic_score_gemma":0.0065281563,"teacher_disagreement_score":0.18750547,"about_ca_system_score_codex":0.0010749304,"about_ca_system_score_gemma":0.0011389958,"threshold_uncertainty_score":0.9246773},"labels":[],"label_agreement":null},{"id":"W3191554850","doi":"10.1177/17588359211036544","title":"IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Gemcitabine; Clinical endpoint; Oncology; Chemotherapy; Internal medicine; Tumor microenvironment; Cancer; Immunotherapy; Clinical trial; Nivolumab","score_opus":0.011651884807790922,"score_gpt":0.33780044466591547,"score_spread":0.3261485598581245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3191554850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97637326,0.016264224,0.00011215262,0.004477582,0.00021601256,0.0017611433,0.000009855665,0.000021795364,0.000764006],"genre_scores_gemma":[0.9836195,0.013435965,0.0005465235,0.0018393452,0.000076177435,0.0003782299,0.000027255428,0.000032236258,0.000044756784],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99749976,0.00031333586,0.00070903526,0.00048318272,0.0006003777,0.0003943205],"domain_scores_gemma":[0.9984328,0.0007097904,0.00026476404,0.0002629648,0.00016594959,0.0001637324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004584745,0.00029649778,0.0019123363,0.00015124828,0.000049961927,0.0000035990784,0.000112821275,0.00019194504,0.0002515432],"category_scores_gemma":[0.00016593347,0.00018821341,0.00009110259,0.0004433282,0.00088985165,0.00012558377,0.00005278041,0.00047593782,3.5290444e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6220774,0.0040599974,0.011930657,0.00009138121,0.00022476476,0.0001917111,0.0013774252,0.000004339158,0.000022380074,0.0000760559,0.000004081866,0.3599398],"study_design_scores_gemma":[0.9512857,0.021728028,0.021621618,0.0004664159,0.0002364826,0.0000373351,0.0004484524,0.00011544563,0.00022184012,0.00035547794,0.0032584516,0.00022471313],"about_ca_topic_score_codex":0.00004594435,"about_ca_topic_score_gemma":0.00059222605,"teacher_disagreement_score":0.3597151,"about_ca_system_score_codex":0.00022359325,"about_ca_system_score_gemma":0.0009157901,"threshold_uncertainty_score":0.76751196},"labels":[],"label_agreement":null},{"id":"W3195299022","doi":"10.1177/17588359211039052","title":"Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Urothelial carcinoma; Carcinoma; Cancer research; Oncology; Bladder cancer; Internal medicine; Cancer","score_opus":0.09591219510996234,"score_gpt":0.4072967351049521,"score_spread":0.3113845399949898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195299022","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017156887,0.9913728,0.00035718287,0.0004953008,0.0002461095,0.0014019927,0.00001120613,0.0000067112437,0.0059370813],"genre_scores_gemma":[0.003726918,0.99378926,0.000992495,0.0007035467,0.0001674255,0.00050598616,0.00003178305,0.0000351834,0.000047402005],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975502,0.0003162193,0.0007823824,0.00048190248,0.0005141363,0.00035519598],"domain_scores_gemma":[0.99864966,0.0006335935,0.00023507047,0.0003600366,0.000021575383,0.00010009138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071949395,0.00034179148,0.0019665018,0.00017571199,0.000031101317,0.00000491693,0.0003303746,0.000369084,0.0001246633],"category_scores_gemma":[0.00003412816,0.00021006801,0.00018675973,0.00047238267,0.00038373464,0.000047224454,0.00013486002,0.0007147522,0.000002933851],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004947634,0.00062510604,0.000114538256,0.008531822,0.00023704549,0.00066318753,0.00074904255,6.198646e-7,5.6328867e-7,0.0005924317,0.0000037385716,0.9884324],"study_design_scores_gemma":[0.004404988,0.00075985136,0.00073811354,0.013091683,0.0014478207,0.0004806655,0.0020242603,0.000024026911,0.0000022369986,0.00024726696,0.9765386,0.00024050384],"about_ca_topic_score_codex":0.000044088516,"about_ca_topic_score_gemma":0.00012045185,"teacher_disagreement_score":0.9881919,"about_ca_system_score_codex":0.00022341059,"about_ca_system_score_gemma":0.00091800216,"threshold_uncertainty_score":0.8566325},"labels":[],"label_agreement":null},{"id":"W3195679999","doi":"10.1177/17588359211035959","title":"The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Molecular pathology; Subtyping; Medicine; Endometrial cancer; Molecular diagnostics; Targeted therapy; Bioinformatics; Molecular marker; Cancer; Oncology; Internal medicine; Computational biology; Pathology; Biology; Gene; Genetics; Computer science","score_opus":0.04628385487803262,"score_gpt":0.4449737521368726,"score_spread":0.39868989725884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195679999","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008008353,0.99562603,0.000022112643,0.00035006448,0.0010029894,0.0013211652,0.000012376241,0.000009532317,0.0008549161],"genre_scores_gemma":[0.009430268,0.98913425,0.000042165077,0.000097804375,0.0003011337,0.00091220735,0.00001524374,0.000034677145,0.000032265038],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951128,0.001732647,0.0016465222,0.0004275269,0.0006104475,0.0004701072],"domain_scores_gemma":[0.99165535,0.006893193,0.00081522716,0.00044902362,0.000082105485,0.00010508534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001259407,0.00036667017,0.0036771642,0.00031307075,0.000049616374,0.0000032259145,0.00037932314,0.00048680033,0.00017339799],"category_scores_gemma":[0.00095020013,0.00017124922,0.00054718455,0.0016275342,0.00048535486,0.000023601957,0.00009164273,0.00058232003,0.0000017686198],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029863336,0.000487054,0.00025881146,0.0013889235,0.00046632357,0.0004043231,0.00027167881,0.0000060774037,0.00001682791,0.0003804915,3.4427202e-7,0.9960205],"study_design_scores_gemma":[0.0061845863,0.0016993524,0.000021804157,0.009091485,0.0014686125,0.0003852855,0.00071409467,0.000013387244,0.00009183413,0.00036862204,0.97979695,0.00016399147],"about_ca_topic_score_codex":0.00022756233,"about_ca_topic_score_gemma":0.00037314874,"teacher_disagreement_score":0.9958565,"about_ca_system_score_codex":0.001047556,"about_ca_system_score_gemma":0.0015751318,"threshold_uncertainty_score":0.6983341},"labels":[],"label_agreement":null},{"id":"W3199693232","doi":"10.1177/17588359211034708","title":"New approaches to first-line treatment of advanced renal cell carcinoma","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Exelixis","keywords":"Axitinib; Medicine; Nivolumab; Pazopanib; Pembrolizumab; Cabozantinib; Sunitinib; Ipilimumab; Renal cell carcinoma; Oncology; Tyrosine-kinase inhibitor; Internal medicine; Avelumab; Kidney cancer; Lenvatinib; Immunotherapy; Cancer","score_opus":0.16901093999069464,"score_gpt":0.39927029872998737,"score_spread":0.23025935873929274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199693232","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020100706,0.9894588,0.0010812853,0.0011269609,0.0004980275,0.0024710458,0.00001885833,0.00003634287,0.0051076747],"genre_scores_gemma":[0.0008689153,0.9870364,0.008703782,0.0002628952,0.0005951831,0.0006225984,0.00026211038,0.000111595364,0.0015365286],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950089,0.0005102787,0.00173871,0.0010889003,0.0008933981,0.0007598489],"domain_scores_gemma":[0.99618113,0.0013101501,0.0005727444,0.00095330767,0.000053696574,0.0009289998],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003545188,0.00088625273,0.005907214,0.00044222013,0.000042220232,0.000005570181,0.00042464797,0.00091815094,0.0009834861],"category_scores_gemma":[0.000100042715,0.00060691696,0.00085501437,0.00086330815,0.00023817694,0.000058878155,0.00014167311,0.00063016696,0.000062669846],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034891823,0.0018117672,0.00004509933,0.0047927056,0.0002289514,0.0019588117,0.00033095118,0.00003378631,0.0000014003155,0.00020690673,0.0000343729,0.9902063],"study_design_scores_gemma":[0.004638056,0.01034142,0.000029695319,0.0051784264,0.0018010295,0.00059201097,0.000078105906,0.000011555922,0.00014415069,0.0001265523,0.97665614,0.00040283232],"about_ca_topic_score_codex":0.000051194787,"about_ca_topic_score_gemma":0.00021129237,"teacher_disagreement_score":0.9898035,"about_ca_system_score_codex":0.0022083714,"about_ca_system_score_gemma":0.0042136554,"threshold_uncertainty_score":0.9999297},"labels":[],"label_agreement":null},{"id":"W3202940729","doi":"10.1177/17588359211047352","title":"Metastatic Urothelial Cancer: a rapidly changing treatment landscape","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Urothelial cancer; Immunotherapy; Clinical trial; Oncology; Chemotherapy; Disease; Cancer; Internal medicine; Intensive care medicine; Bladder cancer; Urothelial carcinoma","score_opus":0.06794330522167166,"score_gpt":0.45002674657035063,"score_spread":0.382083441348679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202940729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005270002,0.99182296,0.00023558774,0.0007403705,0.0013539058,0.0017023672,0.00007354908,0.00007709854,0.003988894],"genre_scores_gemma":[0.00002908967,0.9933809,0.00041076957,0.001517966,0.001098849,0.002190909,0.00015351479,0.000120839715,0.0010971717],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957273,0.00071913836,0.0010745103,0.00085090025,0.0007124457,0.0009157005],"domain_scores_gemma":[0.99781126,0.0008223364,0.0003574659,0.0005058432,0.00006138186,0.00044170703],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047982312,0.0007679282,0.0048359595,0.00049578457,0.00008238496,0.000013661124,0.00029714624,0.00059455034,0.004923851],"category_scores_gemma":[0.00008913102,0.000506514,0.00071573793,0.0008755055,0.00026092355,0.00007910856,0.000087838365,0.0008119365,0.00008497536],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013770936,0.00092677353,0.000033041593,0.0036519119,0.0010940074,0.0024500473,0.00030570445,0.0000011196479,1.4530039e-7,0.00017570921,0.00003415394,0.99118966],"study_design_scores_gemma":[0.005128925,0.0017863263,0.000001843911,0.011972473,0.0038745806,0.0009701292,0.00016576823,0.000028379225,0.0000022739664,0.00009589373,0.9756038,0.0003695694],"about_ca_topic_score_codex":0.00005300783,"about_ca_topic_score_gemma":0.00023727739,"teacher_disagreement_score":0.9908201,"about_ca_system_score_codex":0.0014737326,"about_ca_system_score_gemma":0.006274284,"threshold_uncertainty_score":0.99973863},"labels":[],"label_agreement":null},{"id":"W3203798531","doi":"10.1177/17588359211039928","title":"ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Post-hoc analysis; Internal medicine; Placebo; Pembrolizumab; Hazard ratio; Hepatocellular carcinoma; Confidence interval; Hepatology; Gastroenterology; Liver function; Sorafenib; Cancer; Pathology","score_opus":0.018507011407171443,"score_gpt":0.2851676526289131,"score_spread":0.26666064122174166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203798531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839346,0.00999792,0.0000697079,0.0020153576,0.00019277685,0.0032501707,0.0000067387073,0.000011001116,0.00052172097],"genre_scores_gemma":[0.9970869,0.0009204058,0.00015749737,0.0012249835,0.00003288708,0.0003889483,0.000047499103,0.000018105238,0.00012277445],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961596,0.0013406366,0.001017825,0.00040143466,0.0007445278,0.00033594784],"domain_scores_gemma":[0.9966027,0.0023623656,0.00033731604,0.0003698479,0.00017280469,0.00015496805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012732276,0.000273609,0.0035314837,0.00027620167,0.000043320997,0.000006111241,0.00015926077,0.00027016035,0.00045519904],"category_scores_gemma":[0.0007433671,0.00013968861,0.00050596613,0.0009221406,0.0006993076,0.00006831799,0.000077556535,0.00039950342,0.0000017123696],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.412991,0.00094905053,0.57463324,0.000023259769,0.00088553363,0.00016132636,0.00019452123,0.0000017041863,0.0000040243485,0.00008180254,3.6325997e-7,0.010074187],"study_design_scores_gemma":[0.8746054,0.0019128532,0.11601812,0.00007376271,0.0040446003,0.000006004923,0.00008876459,0.0024687788,0.00005774183,0.00013288412,0.00045417948,0.00013689011],"about_ca_topic_score_codex":0.000055123146,"about_ca_topic_score_gemma":0.000416474,"teacher_disagreement_score":0.46161443,"about_ca_system_score_codex":0.00012858731,"about_ca_system_score_gemma":0.0005917323,"threshold_uncertainty_score":0.5696336},"labels":[],"label_agreement":null},{"id":"W3208960913","doi":"10.1177/17588359211051870","title":"Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Systemic therapy; Hormone therapy; Internal medicine; Clinical trial; Radiation therapy; Prostate-specific antigen; Disease; Cancer; Breast cancer","score_opus":0.10205391747517757,"score_gpt":0.459568545127229,"score_spread":0.35751462765205144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208960913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018049736,0.9772992,0.000030422863,0.0009942105,0.00007106841,0.003204205,0.00004860086,0.00003115359,0.0002714192],"genre_scores_gemma":[0.0026952145,0.99412704,0.00014102404,0.00071935763,0.000082383114,0.0016761392,0.00015051456,0.000090034446,0.00031831884],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99651456,0.00061554986,0.0007460777,0.000845045,0.00065513345,0.00062365644],"domain_scores_gemma":[0.9984609,0.00059329835,0.00028133238,0.00029601526,0.00007058071,0.00029789706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053570134,0.0005947893,0.002576159,0.00035631604,0.00007498996,0.00002258091,0.00013657277,0.000629831,0.00012633437],"category_scores_gemma":[0.000030773354,0.00034472125,0.0001052674,0.0005284166,0.0006349725,0.00013685336,0.00007207219,0.0007185525,0.0000017758616],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013229419,0.00056421285,0.01229371,0.0020596345,0.0010122884,0.0011576434,0.0010903616,0.000001161953,0.0000042606252,0.00003419768,0.0000032071646,0.98045635],"study_design_scores_gemma":[0.03469735,0.0054110666,0.00092829514,0.03447172,0.0020862708,0.0022485233,0.0017474219,0.00016786555,0.000033016742,0.00015350325,0.9172835,0.000771515],"about_ca_topic_score_codex":0.00031144771,"about_ca_topic_score_gemma":0.0005409923,"teacher_disagreement_score":0.9796849,"about_ca_system_score_codex":0.001494566,"about_ca_system_score_gemma":0.0018934289,"threshold_uncertainty_score":0.99990046},"labels":[],"label_agreement":null},{"id":"W3211652415","doi":"10.1177/17588359211056306","title":"The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Ottawa; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; William Osler Health System; McMaster University; Ottawa Hospital; University Health Network; Dalhousie University; University of Toronto; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"AstraZeneca Canada; Pfizer","keywords":"Medicine; Lung cancer; Adjuvant; Oncology; Internal medicine; Cancer research; Pathology","score_opus":0.035450366814115994,"score_gpt":0.46102181578405454,"score_spread":0.42557144896993854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211652415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016593894,0.9922226,0.0002821173,0.0014074959,0.000760255,0.00157845,0.000016923825,0.00001602667,0.0035501742],"genre_scores_gemma":[0.000282933,0.9965313,0.00035669724,0.00063483085,0.00034089974,0.00068633124,0.00013601653,0.000047238067,0.0009837414],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969339,0.00045015782,0.0011841375,0.00047435428,0.00048263144,0.0004748617],"domain_scores_gemma":[0.9975887,0.0012090157,0.00048638685,0.0003954066,0.00010141822,0.00021909225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055127876,0.00035193964,0.0021986582,0.00021717978,0.00005903522,0.00000725439,0.00020618772,0.0005915093,0.00047198884],"category_scores_gemma":[0.0001641624,0.00021336233,0.0002515706,0.00082618423,0.0002906442,0.00005683107,0.000088313725,0.001207289,0.0000055822543],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084751286,0.00040173117,0.000107433545,0.0036665183,0.00020279999,0.00049611466,0.00057859195,0.000007144216,0.0000020402804,0.00016131396,0.00023190274,0.9940597],"study_design_scores_gemma":[0.0035622914,0.00042969442,0.00007915027,0.019956922,0.0012802612,0.00008885591,0.00022353245,0.00006966002,0.000009148806,0.00020901351,0.9739121,0.00017932754],"about_ca_topic_score_codex":0.00041253673,"about_ca_topic_score_gemma":0.0037465286,"teacher_disagreement_score":0.99388033,"about_ca_system_score_codex":0.0014218445,"about_ca_system_score_gemma":0.009664581,"threshold_uncertainty_score":0.9959497},"labels":[],"label_agreement":null},{"id":"W4205192276","doi":"10.1177/17588359211072621","title":"Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Instituto de Salud Carlos III; Junta de Comunidades de Castilla-La Mancha","keywords":"Immunoglobulin superfamily; Carcinoembryonic antigen; Medicine; Cell adhesion molecule; Immune system; Antibody; Cancer research; Cell adhesion; Cancer; Immunology; Oncology; Cell; Bioinformatics; Internal medicine; Biology; Genetics","score_opus":0.059358061318217074,"score_gpt":0.43265147252634983,"score_spread":0.37329341120813275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205192276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5031008,0.34135637,0.002461187,0.13747174,0.0005708613,0.0030731382,0.0001094233,0.00008494613,0.011771528],"genre_scores_gemma":[0.9940984,0.0011931335,0.00034765527,0.0030677668,0.00004105428,0.0010467103,0.00001022045,0.000010204235,0.00018484722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778205,0.00042343806,0.0006319181,0.0002796729,0.00060247607,0.00028044314],"domain_scores_gemma":[0.99859226,0.0007510713,0.00018399915,0.00033643175,0.000028387349,0.00010783741],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009832904,0.00013204446,0.0010104966,0.00010144841,0.000070327646,0.0000012192043,0.00043243298,0.00010006558,0.005193698],"category_scores_gemma":[0.000175682,0.000086094355,0.0004143541,0.001640789,0.00043588164,0.00002964512,0.00014053246,0.0009286456,0.0000012908258],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004167656,0.0221494,0.33412197,0.0012060587,0.10113586,0.00093464693,0.00474276,0.10793207,0.024632072,0.06273614,0.00015536859,0.336086],"study_design_scores_gemma":[0.010722182,0.001443849,0.06418328,0.000060104656,0.1472749,0.00035450733,0.0025364289,0.0548809,0.017574945,0.030255847,0.6699003,0.00081276323],"about_ca_topic_score_codex":0.00005254653,"about_ca_topic_score_gemma":0.000035831265,"teacher_disagreement_score":0.6697449,"about_ca_system_score_codex":0.0002551074,"about_ca_system_score_gemma":0.00046287928,"threshold_uncertainty_score":0.9957157},"labels":[],"label_agreement":null},{"id":"W4205632236","doi":"10.1177/17588359211059601","title":"Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline <i>BRCA1</i> / <i>2</i> mutations and hormone receptor status from the phase-3 BROCADE3 trial","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Aptitude Health; AbbVie","keywords":"Hazard ratio; Veliparib; Breast cancer; Metastatic breast cancer; Clinical endpoint; Placebo; BRCA mutation; Germline mutation","score_opus":0.026685671906534997,"score_gpt":0.392095379246344,"score_spread":0.36540970733980904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205632236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95167816,0.03669081,0.0032473279,0.005014655,0.00025809626,0.001757726,0.0012191662,0.000031532778,0.000102513404],"genre_scores_gemma":[0.9517725,0.04028705,0.0033164374,0.0036401511,0.00014385371,0.00028939277,0.00046716494,0.000050307335,0.000033158827],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99623203,0.00075178064,0.0011387785,0.00061476126,0.00077303353,0.000489621],"domain_scores_gemma":[0.9941836,0.004485149,0.00048793704,0.00030654197,0.00023736547,0.00029940152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047573177,0.00034725244,0.0013115425,0.00010014847,0.00009366125,0.000011045759,0.0001540424,0.00019519601,0.00042685826],"category_scores_gemma":[0.00048429772,0.00022324586,0.000060844464,0.0007928552,0.0013563902,0.00021384715,0.00006127159,0.0007249322,9.264098e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36913848,0.0037969942,0.007409877,0.00009544042,0.0008220122,0.000100875426,0.0036258262,0.0004179586,0.0021748492,0.00009134481,0.00010671563,0.61221963],"study_design_scores_gemma":[0.87500465,0.013418138,0.0690365,0.001497107,0.0010688864,0.00007965499,0.0048396112,0.0015811236,0.0017382265,0.0009792494,0.02993872,0.0008181622],"about_ca_topic_score_codex":0.0005834138,"about_ca_topic_score_gemma":0.002391572,"teacher_disagreement_score":0.6114015,"about_ca_system_score_codex":0.0004997524,"about_ca_system_score_gemma":0.0015563896,"threshold_uncertainty_score":0.91037023},"labels":[],"label_agreement":null},{"id":"W4205813526","doi":"10.1177/17588359211066677","title":"Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Calgary; Université Laval; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Toronto; Dalhousie University; University of British Columbia; BC Cancer Agency","funders":"F. Hoffmann-La Roche; AstraZeneca; Mylan; Pfizer","keywords":"Medicine; Trastuzumab; Neratinib; Oncology; Capecitabine; Internal medicine; Breast cancer; Hazard ratio; Clinical trial; Metastatic breast cancer; Cancer; Progression-free survival; Overall survival; Confidence interval; Colorectal cancer","score_opus":0.053771382150858645,"score_gpt":0.4747381370782596,"score_spread":0.420966754927401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205813526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017827857,0.99058783,0.000009665972,0.0051391074,0.001378048,0.0020792529,0.00009825947,0.000028462826,0.0005010656],"genre_scores_gemma":[0.00034214524,0.9961335,0.00007811446,0.00073549536,0.001183982,0.0013382903,0.00008217014,0.000083192266,0.00002309159],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942975,0.0017029959,0.0013008518,0.00075437943,0.0012208216,0.0007234372],"domain_scores_gemma":[0.99668247,0.0019249856,0.00051796495,0.00053042674,0.000100274076,0.00024388939],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002064392,0.00053306646,0.0029602258,0.00043395476,0.00009538966,0.000008070926,0.0007205194,0.0005535769,0.0025898332],"category_scores_gemma":[0.00014757931,0.0003230261,0.0002541678,0.0013963019,0.00083218503,0.0000922792,0.0002651295,0.0035131196,0.0000026598868],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006390557,0.00043739405,0.00066486903,0.003933098,0.00013294817,0.00018240816,0.00065144344,0.000003884583,0.0000010680999,0.00010510591,0.000042436743,0.99320626],"study_design_scores_gemma":[0.002482198,0.0009977864,0.0006097439,0.007690889,0.0001501441,0.00037822372,0.0005722809,0.000053774547,0.0000012097769,0.00017386352,0.9866175,0.0002723619],"about_ca_topic_score_codex":0.00007537144,"about_ca_topic_score_gemma":0.00029976422,"teacher_disagreement_score":0.9929339,"about_ca_system_score_codex":0.00082086545,"about_ca_system_score_gemma":0.003330751,"threshold_uncertainty_score":0.99992216},"labels":[],"label_agreement":null},{"id":"W4214529556","doi":"10.1177/17588359221081203","title":"Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Breast cancer; Covariate; Quality of life (healthcare); Repeated measures design; Cancer; Gerontology; Correlation; Analysis of variance; Demography; Physical therapy; Internal medicine; Oncology; Statistics; Mathematics","score_opus":0.014106568739178604,"score_gpt":0.31911265260787114,"score_spread":0.30500608386869255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214529556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98133296,0.008823275,0.00043520768,0.007527919,0.00057761313,0.0009773356,0.000080282996,0.00002480802,0.00022061281],"genre_scores_gemma":[0.99587953,0.002056414,0.000081458595,0.0007824992,0.0005272166,0.00056452985,0.000021928745,0.000023770397,0.000062622974],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99758,0.00049816276,0.00040298584,0.00044342646,0.00073851895,0.0003369194],"domain_scores_gemma":[0.9982349,0.0010318361,0.00024520495,0.0002650614,0.00005652358,0.0001664656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001009502,0.0001934901,0.0006577197,0.000055156193,0.00013479461,0.0000048637407,0.000149139,0.00012121917,0.0004968353],"category_scores_gemma":[0.00006446245,0.0001302062,0.000023904504,0.0004050156,0.00082514994,0.000116470845,0.00013802864,0.00073537946,3.7345296e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06572144,0.00032408405,0.25672147,0.000046309306,0.00016268111,0.00004714484,0.0047164294,0.000102974365,0.00003991415,0.00012270888,0.000009442818,0.67198545],"study_design_scores_gemma":[0.07322601,0.009712462,0.79812586,0.0003131399,0.00044017003,0.00018288987,0.00678543,0.00011509686,0.000034965193,0.0054038255,0.10520042,0.00045970076],"about_ca_topic_score_codex":0.00037293127,"about_ca_topic_score_gemma":0.0019075107,"teacher_disagreement_score":0.6715257,"about_ca_system_score_codex":0.00040686104,"about_ca_system_score_gemma":0.0004945119,"threshold_uncertainty_score":0.5439998},"labels":[],"label_agreement":null},{"id":"W4285189908","doi":"10.1177/17588359221108685","title":"Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Calgary; Queen Elizabeth II Health Sciences Centre; McMaster University; Juravinski Cancer Centre","funders":"Pfizer Canada; Merck Canada; Ipsen; Eisai","keywords":"Medicine; Cancer therapy; Systematic review; Cancer; Kidney cancer; Oncology; MEDLINE; Intensive care medicine; Internal medicine","score_opus":0.061614521457701237,"score_gpt":0.4158854827627571,"score_spread":0.35427096130505586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285189908","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000036601115,0.99189144,0.000039812152,0.0005987637,0.00037609262,0.0057973717,0.000013133619,0.000033691595,0.0012131003],"genre_scores_gemma":[0.00035426056,0.9934705,0.00010985735,0.0008162138,0.0000752751,0.0048105414,0.00018305022,0.00007535938,0.00010495357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99331445,0.0015985357,0.002724215,0.00065341126,0.0012058826,0.00050349475],"domain_scores_gemma":[0.9946799,0.0028847863,0.001489329,0.0006627668,0.00009334876,0.00018984455],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023678283,0.0005885386,0.0072011906,0.00054593186,0.000045507295,0.0000034399184,0.0005509288,0.00044964207,0.0028315287],"category_scores_gemma":[0.00084085134,0.00040235274,0.0005130731,0.0012511269,0.0002001216,0.000103327904,0.0001238643,0.0013492476,0.000008019097],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109541776,0.0006387136,0.00006033639,0.38960737,0.00016488449,0.00035346343,0.00006842961,0.0000056673925,1.2994607e-7,0.000042039628,0.000008633073,0.6089408],"study_design_scores_gemma":[0.0034656853,0.0024424528,0.000013890734,0.4623671,0.0013598339,0.00031483086,0.000039548046,0.00012569965,8.540651e-7,0.00013892261,0.52946794,0.00026321833],"about_ca_topic_score_codex":0.000031748008,"about_ca_topic_score_gemma":0.00022983436,"teacher_disagreement_score":0.60867757,"about_ca_system_score_codex":0.001900806,"about_ca_system_score_gemma":0.0015178852,"threshold_uncertainty_score":0.9998428},"labels":[],"label_agreement":null},{"id":"W4285229704","doi":"10.1177/17588359221097940","title":"Characterizing the <i>KRAS</i> G12C mutation in metastatic colorectal cancer: a population-based cohort and assessment of expression differences in The Cancer Genome Atlas","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"KRAS; Medicine; Colorectal cancer; Population; Cancer; Oncology; Internal medicine; Mutation; Cancer research; Gene; Biology; Genetics","score_opus":0.02920145447641013,"score_gpt":0.38917827841675795,"score_spread":0.3599768239403478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285229704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97680956,0.014388316,0.000039838258,0.0073116785,0.00019571424,0.0009878727,0.000019225656,0.0000069053494,0.00024088038],"genre_scores_gemma":[0.98889524,0.006506765,0.00010654665,0.0018882884,0.0000371652,0.0025255133,0.000026671198,0.000008569291,0.000005227886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978234,0.00064791954,0.000464328,0.00026535874,0.00056938035,0.00022959104],"domain_scores_gemma":[0.99851555,0.0011087365,0.0002085097,0.00010544801,0.000023782442,0.00003797842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095073413,0.00014660333,0.00056151336,0.000112237285,0.00012606628,0.000005036684,0.00017073553,0.00004475272,0.00027504587],"category_scores_gemma":[0.000051687523,0.000079722275,0.000038484388,0.00038550547,0.0002176684,0.000056643683,0.00006964156,0.00046977057,8.2003034e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063152995,0.00046965017,0.8919613,0.000061674706,0.000055149565,0.00008854379,0.0031534005,0.00025851856,0.0007560595,0.00009406762,0.000001334522,0.10246877],"study_design_scores_gemma":[0.002463002,0.0009608225,0.9883179,0.00010364307,0.00008230142,0.000019221645,0.0025518166,0.0029965031,0.00004979045,0.00032679527,0.002046488,0.00008168623],"about_ca_topic_score_codex":0.0016630957,"about_ca_topic_score_gemma":0.007296206,"teacher_disagreement_score":0.102387086,"about_ca_system_score_codex":0.0006361798,"about_ca_system_score_gemma":0.00047722715,"threshold_uncertainty_score":0.40714544},"labels":[],"label_agreement":null},{"id":"W4285270205","doi":"10.1177/17588359221094879","title":"The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Metastatic Urothelial Carcinoma; Medicine; Chemotherapy; Urothelial carcinoma; Oncology; Metastasis; Bone metastasis; Internal medicine; First line; Carcinoma; Cancer research; Cancer; Bladder cancer","score_opus":0.01586903876166198,"score_gpt":0.32684249620395206,"score_spread":0.3109734574422901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285270205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280125,0.0031237348,0.00039631585,0.0014052774,0.00006374551,0.0018433898,0.00006597486,0.000026839502,0.00027349818],"genre_scores_gemma":[0.9975829,0.0002902582,0.0005183535,0.0008121274,0.000028808556,0.0006288258,0.00005992549,0.000051148,0.000027637632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971331,0.00042455556,0.00061544793,0.00037177614,0.0009518234,0.00050331326],"domain_scores_gemma":[0.99799013,0.0011321475,0.00028751482,0.00033541265,0.00008979612,0.00016497652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005455213,0.00031213035,0.000913205,0.00020406414,0.00013241138,0.000004911982,0.00021493521,0.00006835027,0.0007824505],"category_scores_gemma":[0.00009494144,0.00016286947,0.00011213901,0.0007789157,0.0005111903,0.00006722774,0.000034978893,0.0005136602,0.000001583841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027988778,0.003306807,0.8084892,0.00006601062,0.0003850538,0.00029324755,0.0003623108,0.0013929042,0.000008929956,0.000027248867,0.0000076013275,0.15767193],"study_design_scores_gemma":[0.084734514,0.058056943,0.84798175,0.00020912432,0.0006207875,0.000111062705,0.0003184608,0.0018565311,0.00019473002,0.00035874578,0.0051878565,0.00036946413],"about_ca_topic_score_codex":0.0003229951,"about_ca_topic_score_gemma":0.0009605931,"teacher_disagreement_score":0.15730247,"about_ca_system_score_codex":0.0007013738,"about_ca_system_score_gemma":0.0015823637,"threshold_uncertainty_score":0.85672843},"labels":[],"label_agreement":null},{"id":"W4286357580","doi":"10.1177/17588359221111705","title":"Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Queen Elizabeth II Health Sciences Centre; William Osler Health System; University of Alberta; Surrey Memorial Hospital","funders":"Pfizer Canada; Amgen Canada; Thermo Scientific","keywords":"KRAS; Medicine; Colorectal cancer; Biomarker; Oncology; Guideline; Targeted therapy; Biomarker discovery; Cancer; Internal medicine; Bioinformatics; Pathology; Gene; Biology","score_opus":0.13394123132511457,"score_gpt":0.49144521244157596,"score_spread":0.3575039811164614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286357580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000062499753,0.980915,0.000043647433,0.0057705357,0.0013758724,0.0034068173,0.00027550495,0.000055311622,0.008151048],"genre_scores_gemma":[0.000032575183,0.980278,0.0061137374,0.007112412,0.00030474033,0.00573717,0.00018779044,0.00009657802,0.0001370067],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953873,0.00069783814,0.0015583647,0.00078147766,0.0006438783,0.0009311236],"domain_scores_gemma":[0.98761123,0.010604199,0.0007394188,0.0002583198,0.00022890982,0.0005579159],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018162241,0.0006078238,0.0034341493,0.00043927738,0.00026950386,0.000010447024,0.00032093565,0.0002645503,0.0019532098],"category_scores_gemma":[0.0057690255,0.00044926043,0.00036651088,0.0009478049,0.00048996956,0.000054960085,0.00012513214,0.0010171762,0.00000942759],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0006206538,0.0003655685,0.000024205687,0.0026566503,0.0010515326,0.0026598736,0.0001038142,0.0000018780742,1.336059e-7,0.00007840582,0.001142137,0.99129516],"study_design_scores_gemma":[0.0027664374,0.0027731257,0.0000076044353,0.0020383513,0.0038051815,0.0026269518,0.00044676304,0.0002501506,1.1678817e-7,0.00017232193,0.9847336,0.00037941572],"about_ca_topic_score_codex":0.012705434,"about_ca_topic_score_gemma":0.09420539,"teacher_disagreement_score":0.9909157,"about_ca_system_score_codex":0.004500579,"about_ca_system_score_gemma":0.014877804,"threshold_uncertainty_score":0.9997959},"labels":[],"label_agreement":null},{"id":"W4288013778","doi":"10.1177/17588359221112696","title":"The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Niagara Health System; University of Toronto; Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; University of Ottawa; Jewish General Hospital; McMaster University; Juravinski Cancer Centre; McGill University; University of Calgary","funders":"Jewish General Hospital; BC Cancer Foundation; Princess Margaret Cancer Foundation; Guardant Health; Ottawa Hospital Research Institute","keywords":"Liquid biopsy; Medicine; Lung cancer; Biopsy; Circulating tumor DNA; Cell-free fetal DNA; Lung; Oncology; Pathology; Cancer research; Internal medicine; Cancer; Biology; Genetics","score_opus":0.008545333577232495,"score_gpt":0.31906501960689143,"score_spread":0.31051968602965896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288013778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9507952,0.044003088,0.0021964868,0.00063338305,0.0010907154,0.0007644317,0.00006236918,0.00000382822,0.00045050858],"genre_scores_gemma":[0.9725225,0.023274379,0.0016685722,0.00096524647,0.00024501162,0.0011932262,0.000038026723,0.000033424774,0.000059588492],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852866,0.00012231429,0.0005012975,0.00035266322,0.00010955407,0.00038552296],"domain_scores_gemma":[0.9990189,0.00041825493,0.00021847677,0.00025195943,0.000024601622,0.0000678227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079161307,0.0001469227,0.00030545925,0.000056250046,0.00010732067,0.00000386845,0.00051177404,0.00013213592,0.000042719854],"category_scores_gemma":[0.000064946296,0.00013029104,0.000082321974,0.00008190808,0.00018174038,0.0000038122514,0.00024373794,0.00024881627,5.256986e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010080261,0.0007299522,0.02420177,0.000329819,0.00016775224,0.00003860425,0.00094995386,0.2807542,0.34263206,0.007381156,0.00017666846,0.3325578],"study_design_scores_gemma":[0.0135416435,0.0064491145,0.001902543,0.00007337444,0.000098298595,0.000044989592,0.0024335484,0.047704846,0.097073205,0.003564041,0.82623374,0.0008806407],"about_ca_topic_score_codex":0.00006758887,"about_ca_topic_score_gemma":0.0007807499,"teacher_disagreement_score":0.8260571,"about_ca_system_score_codex":0.00044586178,"about_ca_system_score_gemma":0.0014272566,"threshold_uncertainty_score":0.53131145},"labels":[],"label_agreement":null},{"id":"W4295904913","doi":"10.1177/17588359221122714","title":"The role of gut microbiome in immune modulation in metastatic renal cell carcinoma","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Microbiome; Immunotherapy; Renal cell carcinoma; Gut microbiome; Immune system; Intensive care medicine; Gut flora; Immunology; Oncology; Bioinformatics; Biology","score_opus":0.032753435061530105,"score_gpt":0.37980260325678,"score_spread":0.3470491681952499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295904913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00085671083,0.9959833,0.00002002294,0.0002544518,0.00041828788,0.0011590532,0.000010430919,0.000008793861,0.0012889422],"genre_scores_gemma":[0.010866681,0.98816115,0.00013230916,0.0002096134,0.00005886114,0.00035985283,0.00008081868,0.000039970586,0.00009073697],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99559945,0.001212133,0.0018239145,0.0003982013,0.00049929036,0.0004670073],"domain_scores_gemma":[0.9970455,0.0018015708,0.00064512086,0.00041928492,0.000020257397,0.00006823592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024811015,0.0003305115,0.0021160285,0.0005003195,0.000046653913,0.0000038861594,0.0005112962,0.0003360216,0.00081696926],"category_scores_gemma":[0.00010288448,0.00021955236,0.00031977813,0.0011048014,0.0005283276,0.00005785109,0.000112943526,0.0012555821,0.000004235585],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093376107,0.00043821975,0.00008879154,0.0016757046,0.00006731976,0.000141303,0.00026818668,0.000005220268,0.00015928294,0.00007326937,0.0000027622555,0.9961462],"study_design_scores_gemma":[0.0032955492,0.0007693792,0.0003263335,0.0017734641,0.00016690223,0.00015216519,0.00036220302,0.0001335894,0.0000185712,0.00065100944,0.9921643,0.00018649592],"about_ca_topic_score_codex":0.00020717763,"about_ca_topic_score_gemma":0.00053042296,"teacher_disagreement_score":0.9959597,"about_ca_system_score_codex":0.001170439,"about_ca_system_score_gemma":0.0016256425,"threshold_uncertainty_score":0.89530855},"labels":[],"label_agreement":null},{"id":"W4296502312","doi":"10.1177/17588359221126151","title":"Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Lung cancer; Internal medicine; Biopsy; Referral; Liquid biopsy; Cancer; Oncology; Clinical endpoint; Cohort study; Pathology; Clinical trial","score_opus":0.018142735730742408,"score_gpt":0.3462831243431265,"score_spread":0.3281403886123841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296502312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8917453,0.099368036,0.0026293586,0.0036755537,0.00080829405,0.00043225187,0.000043523007,0.000017788103,0.0012798435],"genre_scores_gemma":[0.94111407,0.04848601,0.0022841701,0.006058458,0.00029714842,0.0016602159,0.00004443769,0.000037256425,0.000018241604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833304,0.00015673158,0.00035560006,0.00048086885,0.00027706797,0.00039667336],"domain_scores_gemma":[0.99929696,0.00021999449,0.00012976384,0.00020808924,0.00003166271,0.00011353723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039150286,0.00018854823,0.00029581963,0.000045896293,0.00020542755,0.000011642125,0.00031008694,0.00017435788,0.00035417773],"category_scores_gemma":[0.00017211224,0.00019069448,0.000053586944,0.00016549969,0.000220319,0.000009805034,0.00046161845,0.0003778823,7.197176e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042861965,0.0020138544,0.12846981,0.0005341567,0.00064053346,0.0012971488,0.0029828984,0.024284028,0.08285828,0.02448141,0.00132356,0.7268281],"study_design_scores_gemma":[0.0039093993,0.0025457628,0.0002918262,0.00006862947,0.00008842054,0.00021284365,0.00080404384,0.005960148,0.040377144,0.0015716493,0.9434934,0.00067672523],"about_ca_topic_score_codex":0.00006653238,"about_ca_topic_score_gemma":0.00025697003,"teacher_disagreement_score":0.94216985,"about_ca_system_score_codex":0.00016383475,"about_ca_system_score_gemma":0.00038094685,"threshold_uncertainty_score":0.7776295},"labels":[],"label_agreement":null},{"id":"W4308189235","doi":"10.1177/17588359221133893","title":"Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high <i>ACE2</i> -expressing normal lung","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; Canadian Institutes of Health Research; Instituto de Salud Carlos III; Israel Science Foundation; FP7 Health; Sixth Framework Programme; Canadian Cancer Society","keywords":"Medicine; Pneumonia; Lung cancer; Lung; Coronavirus disease 2019 (COVID-19); Gene; Immunology; Comorbidity; Virology; Cancer research; Pathology; Internal medicine; Biology; Genetics; Disease","score_opus":0.03554020693441197,"score_gpt":0.4457092496624502,"score_spread":0.4101690427280382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308189235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8969036,0.08075571,0.0012318811,0.019579567,0.00031731804,0.00089051435,0.00007003321,0.000046710305,0.00020466319],"genre_scores_gemma":[0.9747594,0.018257504,0.00018672623,0.0062287813,0.00016697479,0.0003180093,0.00001881984,0.000026852023,0.00003690379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99582744,0.00086862873,0.0009634662,0.0005348543,0.0011480515,0.00065753603],"domain_scores_gemma":[0.992539,0.0063896677,0.00022742839,0.0003217582,0.000057566594,0.00046459318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027612473,0.00023912235,0.0012307181,0.00025927016,0.00019491752,0.000004082133,0.0004026902,0.0002277192,0.0005758053],"category_scores_gemma":[0.0021070829,0.00021502917,0.00009955062,0.0005148555,0.0014001514,0.0001277385,0.00047103132,0.0016152558,4.3668123e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020613305,0.000794748,0.68690044,0.0009848414,0.00022450648,0.00043545358,0.0026114003,0.001667701,0.0075060236,0.00026695733,0.000045342615,0.29650125],"study_design_scores_gemma":[0.026333028,0.0029509,0.6246883,0.0004952668,0.0005028911,0.000056197692,0.0017412661,0.017122425,0.0012605481,0.005546888,0.31857395,0.00072831224],"about_ca_topic_score_codex":0.0010695995,"about_ca_topic_score_gemma":0.0004533805,"teacher_disagreement_score":0.31852862,"about_ca_system_score_codex":0.0014356766,"about_ca_system_score_gemma":0.0022389153,"threshold_uncertainty_score":0.8768635},"labels":[],"label_agreement":null},{"id":"W4312211783","doi":"10.1177/17588359221143975","title":"Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"BC Cancer Foundation; Michael Smith Health Research BC","keywords":"Medicine; Liquid biopsy; Colorectal cancer; Stage (stratigraphy); Oncology; Minimal residual disease; Circulating tumor DNA; Internal medicine; Cancer; Clinical trial; Disease; Adjuvant; Leukemia","score_opus":0.06832000875268691,"score_gpt":0.42487258444342074,"score_spread":0.35655257569073384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312211783","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007788051,0.9953741,0.0001764292,0.00013814452,0.00086673145,0.0014364184,0.00018224417,0.000014942779,0.0010321737],"genre_scores_gemma":[0.00016740992,0.99473894,0.0004132824,0.001064757,0.0006796758,0.0019466638,0.00044865956,0.000090869566,0.00044974542],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969423,0.00029289778,0.0010498989,0.00075467443,0.00030766847,0.00065260386],"domain_scores_gemma":[0.9978536,0.0010236364,0.0005739742,0.00036294552,0.000033726083,0.00015212577],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011109745,0.00042036534,0.0015347071,0.00017554559,0.000089708854,0.000014068738,0.0006373194,0.0005267427,0.0007967008],"category_scores_gemma":[0.0006754167,0.00036642677,0.00020249459,0.00031703434,0.00018268947,0.0000069819775,0.00033047938,0.0006374899,0.000006013945],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002700476,0.00016772779,0.000030946656,0.0013256329,0.00008390372,0.00016052132,0.000064640146,0.000041233357,0.000074222815,0.00015539488,0.00009775169,0.99752796],"study_design_scores_gemma":[0.001419169,0.0012370707,0.0000031419092,0.00094804756,0.00014092385,0.00005569835,0.000055044457,0.00015403803,0.000018442342,0.000090660295,0.9954671,0.0004106507],"about_ca_topic_score_codex":0.000104641025,"about_ca_topic_score_gemma":0.00090288476,"teacher_disagreement_score":0.99711734,"about_ca_system_score_codex":0.000759058,"about_ca_system_score_gemma":0.0025034486,"threshold_uncertainty_score":0.99987876},"labels":[],"label_agreement":null},{"id":"W4321795635","doi":"10.1177/17588359231152843","title":"Quality of life with ribociclib <i>versus</i> abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"National Cancer Institute; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Medicine; Breast cancer; Internal medicine; Quality of life (healthcare); Oncology; Placebo; Cancer; Hazard ratio; Clinical trial; Confidence interval; Alternative medicine; Pathology","score_opus":0.06506842105089145,"score_gpt":0.4343277424711693,"score_spread":0.36925932142027784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321795635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652327,0.020579748,0.0015919852,0.008743074,0.00077906874,0.0014078253,0.00014351396,0.00030238126,0.0012197547],"genre_scores_gemma":[0.9763013,0.020397743,0.0014494754,0.00091786694,0.00023491305,0.00040719786,0.000070145594,0.00008733965,0.00013400936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99522465,0.00042093146,0.0016197265,0.0007013065,0.0012333796,0.00080000097],"domain_scores_gemma":[0.995541,0.0020925368,0.0010243219,0.0006239654,0.00024849083,0.0004696841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007325589,0.00052675727,0.00273952,0.00034013583,0.0000839114,0.0000038126923,0.00038231825,0.00038844178,0.0007616286],"category_scores_gemma":[0.00018144918,0.00038956545,0.00021482582,0.0015199974,0.0012260741,0.0002269644,0.00008118843,0.0005087343,0.000020808162],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04871656,0.0025943872,0.06100689,0.0006153692,0.00078433857,0.00012675341,0.0031698826,0.0035917878,0.0010382595,0.0005346287,0.00000866717,0.8778125],"study_design_scores_gemma":[0.25979108,0.060246203,0.3574496,0.0049495804,0.0017090956,0.00069327955,0.019948654,0.004180342,0.013287684,0.011104814,0.2636362,0.003003481],"about_ca_topic_score_codex":0.0006269435,"about_ca_topic_score_gemma":0.004144311,"teacher_disagreement_score":0.874809,"about_ca_system_score_codex":0.0008122512,"about_ca_system_score_gemma":0.0014035766,"threshold_uncertainty_score":0.99985564},"labels":[],"label_agreement":null},{"id":"W4323024632","doi":"10.1177/17588359231157644","title":"Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Oncology; Cancer research; Poly ADP ribose polymerase; Internal medicine; Cancer; Pharmacology; DNA; Biology; Genetics","score_opus":0.09070451031767579,"score_gpt":0.4848637584573334,"score_spread":0.39415924813965764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323024632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025789852,0.98710847,0.000095143434,0.0027099098,0.0017878653,0.0020135513,0.00008262711,0.00016149352,0.0060151746],"genre_scores_gemma":[0.00006857803,0.99174094,0.00044474154,0.0015337495,0.0015773356,0.003060272,0.00017239405,0.00016519954,0.0012367686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939951,0.0009140983,0.0020847372,0.0010566303,0.0009179124,0.0010315616],"domain_scores_gemma":[0.9962099,0.0020342239,0.0006877125,0.0005981009,0.000109040935,0.00036100834],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001134455,0.00082050863,0.00418085,0.0007790268,0.000081916805,0.000023018247,0.00044967447,0.0014046209,0.0016082923],"category_scores_gemma":[0.00022089781,0.00061024417,0.00043379288,0.0014270241,0.000600933,0.00021481946,0.000081816695,0.0017105102,0.00014372841],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00047706926,0.00038646773,0.000019656503,0.0066284873,0.0002535174,0.0017129084,0.0005262682,0.000008037991,0.000004811979,0.0013850457,0.000083088315,0.98851466],"study_design_scores_gemma":[0.004848033,0.0008226239,0.000020251182,0.038071506,0.00036537202,0.000118133925,0.00047967336,0.0000102538215,0.0000064926976,0.002517454,0.95226127,0.00047893095],"about_ca_topic_score_codex":0.00016541108,"about_ca_topic_score_gemma":0.0063160756,"teacher_disagreement_score":0.98803574,"about_ca_system_score_codex":0.0049055903,"about_ca_system_score_gemma":0.008329125,"threshold_uncertainty_score":0.99989176},"labels":[],"label_agreement":null},{"id":"W4323063328","doi":"10.1177/17588359231157651","title":"Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia Hospital; University of British Columbia; Pancreas Centre (Canada)","funders":"Terry Fox Research Institute; Genome British Columbia; Pancreatic Cancer Canada Foundation; VGH and UBC Hospital Foundation","keywords":"Liquid biopsy; Medicine; Pancreatic ductal adenocarcinoma; Druggability; Pancreatic cancer; Disease; Clinical trial; Genomics; Bioinformatics; Internal medicine; Oncology; Cancer; Genome; Gene; Biology; Genetics","score_opus":0.08646251333694421,"score_gpt":0.43717743138949516,"score_spread":0.35071491805255095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323063328","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008860347,0.99599147,0.00045738518,0.00023667388,0.0012482562,0.00067636045,0.000028449616,0.000014986308,0.00046036355],"genre_scores_gemma":[0.0072041005,0.99032825,0.00017963407,0.0005738584,0.0013346572,0.00018564746,0.00008710754,0.00007867091,0.000028094404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99598014,0.0007799402,0.0016941519,0.00065652677,0.00037584995,0.0005133645],"domain_scores_gemma":[0.9959116,0.0024532124,0.00079524005,0.00061862863,0.000050953204,0.00017036064],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018432679,0.00039641125,0.0019592326,0.00009108686,0.000061864965,0.0000112632,0.0009327668,0.0007097972,0.0000712512],"category_scores_gemma":[0.0018507205,0.00027561537,0.0005240987,0.0003168051,0.00081617554,0.0000049973783,0.00040033954,0.0008231902,0.000021098116],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045145964,0.00014064617,0.0006147249,0.0024234212,0.00033879338,0.00028740338,0.00007045063,0.00001078612,0.0000043453906,0.00075989054,0.00011335778,0.99519104],"study_design_scores_gemma":[0.00068798626,0.00071116054,0.00026012873,0.0022833429,0.00058180327,0.00041101666,0.00011705487,0.000101889746,0.0000027815781,0.0016962409,0.99279785,0.00034873871],"about_ca_topic_score_codex":0.00002358276,"about_ca_topic_score_gemma":0.00013381327,"teacher_disagreement_score":0.9948423,"about_ca_system_score_codex":0.00013026565,"about_ca_system_score_gemma":0.002093,"threshold_uncertainty_score":0.9999696},"labels":[],"label_agreement":null},{"id":"W4327652478","doi":"10.1177/17588359231160141","title":"Direct GDP-KRAS <sup>G12C</sup> inhibitors and mechanisms of resistance: the tip of the iceberg","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Regeneron Pharmaceuticals; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; KRAS; Iceberg; Cancer research; Internal medicine; Pharmacology; Cancer; Physics","score_opus":0.02494405273547091,"score_gpt":0.3498188310208574,"score_spread":0.3248747782853865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327652478","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007832313,0.99693286,0.00078042713,0.00031814468,0.0002500711,0.0007140775,0.000026022233,0.000009201632,0.0008908691],"genre_scores_gemma":[0.0037675018,0.99504465,0.00013818829,0.00027885943,0.00020311045,0.00013227931,0.000025200121,0.00003913125,0.00037108606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971307,0.0009370376,0.0008509226,0.00038728505,0.00042472457,0.00026931494],"domain_scores_gemma":[0.99830246,0.00049805164,0.00059186626,0.0004780687,0.000056332254,0.00007323365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014977688,0.00028578023,0.0011001081,0.00007522433,0.00007089787,0.0000039109013,0.000574412,0.0006401592,0.000041638836],"category_scores_gemma":[0.0004245225,0.00015506489,0.0002719115,0.00039147728,0.0008229697,0.0000043299224,0.00028316458,0.0004140637,0.0000021832082],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000855397,0.00007907064,0.0000046763457,0.0035750903,0.00018169772,0.000009984095,0.0000922477,0.000028798075,0.00021289702,0.0051350286,0.00009860859,0.99049634],"study_design_scores_gemma":[0.00038038427,0.00017904228,0.0000031604345,0.003271501,0.00018494966,0.000019103561,0.0000935901,0.0000228972,0.0010405154,0.0032933676,0.9913497,0.00016178303],"about_ca_topic_score_codex":0.0000069066227,"about_ca_topic_score_gemma":0.00015493241,"teacher_disagreement_score":0.9912511,"about_ca_system_score_codex":0.000036442147,"about_ca_system_score_gemma":0.0005888582,"threshold_uncertainty_score":0.63233626},"labels":[],"label_agreement":null},{"id":"W4327850169","doi":"10.1177/17588359231157633","title":"A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Western University; Centre Hospitalier de l’Université de Montréal; University of Calgary; University of Manitoba; Princess Margaret Cancer Centre; University of Toronto; University of British Columbia","funders":"Merck Canada; Eisai Canada; Eisai; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Endometrial cancer; Oncology; Internal medicine; Microsatellite instability; Lenvatinib; Metastatic breast cancer; Cancer; Breast cancer; Immunotherapy; Thyroid cancer","score_opus":0.07530303729759415,"score_gpt":0.44368306545161573,"score_spread":0.3683800281540216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327850169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000724576,0.9924265,0.000027113445,0.00048007062,0.002253909,0.0026723791,0.000041752228,0.00013677511,0.001889047],"genre_scores_gemma":[0.000579272,0.9952001,0.00018949555,0.00031333853,0.00093272637,0.002135245,0.00016946155,0.00014350777,0.00033685213],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926113,0.0011944796,0.002920537,0.0009824558,0.001230789,0.001060458],"domain_scores_gemma":[0.9931798,0.004961435,0.0008243233,0.0004821986,0.000086478794,0.0004657412],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024245635,0.0008131818,0.0061889472,0.0019614391,0.000052502433,0.000016461378,0.0005130662,0.00094806775,0.0032524497],"category_scores_gemma":[0.0028469253,0.00055175065,0.0008190706,0.0054785823,0.00035055925,0.00014939898,0.00021325337,0.0021151516,0.00015529426],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076379586,0.0007910192,0.00025600588,0.008058363,0.0007559221,0.0018054759,0.00012038609,0.0000028751456,0.000001349543,0.000028749366,0.000020800217,0.9873953],"study_design_scores_gemma":[0.019634388,0.0018650305,0.00013128233,0.028981246,0.0022242821,0.00020234285,0.00012819716,0.0000777731,0.0000066304337,0.0005667809,0.94561,0.00057208666],"about_ca_topic_score_codex":0.00039847184,"about_ca_topic_score_gemma":0.00082426233,"teacher_disagreement_score":0.98682314,"about_ca_system_score_codex":0.0021214846,"about_ca_system_score_gemma":0.002730507,"threshold_uncertainty_score":0.9996934},"labels":[],"label_agreement":null},{"id":"W4361799923","doi":"10.1177/17588359231162577","title":"Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université de Sherbrooke","funders":"","keywords":"Microsatellite instability; Medicine; DNA mismatch repair; Colorectal cancer; Immune checkpoint; Oncology; Chemotherapy; Adjuvant; Cancer; Immune system; Cancer research; Immunotherapy; Internal medicine; Immunology; Biology; Gene; Genetics","score_opus":0.0512075099216513,"score_gpt":0.41381590591825096,"score_spread":0.36260839599659966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361799923","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000057784648,0.9935815,0.00014664509,0.0020229986,0.00028836526,0.0014924562,0.000005166112,0.000046652483,0.0023584596],"genre_scores_gemma":[0.000103489285,0.9969772,0.0010212146,0.0013667117,0.00009195252,0.00022995839,0.000016296253,0.000027538494,0.00016560771],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970514,0.0003340255,0.0010259475,0.00042969084,0.0006678006,0.00049111043],"domain_scores_gemma":[0.9964834,0.0026889085,0.00040437916,0.0003090541,0.00002449664,0.000089778085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018712786,0.00031893243,0.0018506054,0.00025350376,0.00003451308,0.0000054959987,0.0003447348,0.0001548244,0.000058182624],"category_scores_gemma":[0.0002332546,0.00019952332,0.00023529754,0.00067653693,0.00043831786,0.00003994952,0.00018188043,0.00070854527,0.0000060501993],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009807569,0.00009365019,0.0006361721,0.017669506,0.00014809243,0.0014380593,0.00021161776,0.000008143669,1.600724e-8,0.001235923,0.00025546306,0.97820526],"study_design_scores_gemma":[0.0020548494,0.0006282191,0.00059149845,0.023632474,0.00084048294,0.00039503214,0.0025496613,0.00015999973,1.9018028e-8,0.00023456366,0.96876574,0.0001474563],"about_ca_topic_score_codex":0.000068734305,"about_ca_topic_score_gemma":0.00029293032,"teacher_disagreement_score":0.9780578,"about_ca_system_score_codex":0.00060458825,"about_ca_system_score_gemma":0.00042687316,"threshold_uncertainty_score":0.8136325},"labels":[],"label_agreement":null},{"id":"W4361802115","doi":"10.1177/17588359231152845","title":"Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University Health Centre; Juravinski Cancer Centre; St. Michael's Hospital; University of British Columbia; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Sanofi","keywords":"Medicine; Prostate cancer; Hormonal therapy; Oncology; Hormone therapy; Cancer; Prostate; Internal medicine; Intensive care medicine; Breast cancer","score_opus":0.21126107155521642,"score_gpt":0.5522541500154357,"score_spread":0.3409930784602192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361802115","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018910745,0.9876706,0.00008786901,0.00304463,0.0007205252,0.0073055574,0.00001199989,0.000121415986,0.0010184633],"genre_scores_gemma":[0.0000059933373,0.9758127,0.0005317315,0.013079089,0.00021417248,0.009210092,0.00006347182,0.00009201506,0.0009907491],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937953,0.0007187843,0.0022632056,0.0010981911,0.0011617221,0.0009628114],"domain_scores_gemma":[0.9968584,0.0010560101,0.0006830917,0.0006716958,0.00012457628,0.0006062213],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0020197774,0.00066131697,0.004741021,0.00045983453,0.000048433827,0.000008929886,0.00087702676,0.00060644845,0.0027774496],"category_scores_gemma":[0.0008061031,0.00049265433,0.00029287694,0.002490591,0.00034565988,0.00014746307,0.00016222916,0.001805454,0.001176757],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016515904,0.00022293364,0.00006027262,0.05000806,0.000053647465,0.00036959333,0.00007683331,0.0000015682109,3.9354433e-7,0.00006210165,0.00024860373,0.9487308],"study_design_scores_gemma":[0.0012384647,0.001078931,0.000020355204,0.40731114,0.00008748297,0.00007395913,0.000026576143,0.000010150417,2.6517208e-7,0.00018355962,0.58968234,0.0002868066],"about_ca_topic_score_codex":0.00004379675,"about_ca_topic_score_gemma":0.0004605905,"teacher_disagreement_score":0.948444,"about_ca_system_score_codex":0.00074528926,"about_ca_system_score_gemma":0.006599805,"threshold_uncertainty_score":0.9997525},"labels":[],"label_agreement":null},{"id":"W4361988864","doi":"10.1177/17588359231156382","title":"A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"FP7 Health; Pharmacyclics; Sanofi Genzyme; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Servier; AstraZeneca; Institut National Du Cancer; Canadian Cancer Society; Foundation Medicine; Fondation ARC pour la Recherche sur le Cancer; Seagen; Puma Biotechnology; Actuate Therapeutics; Symphogen; Pfizer; Incyte; Grifols; EQRx; BeiGene; European Commission; Sanofi; Halozyme; Chugai Pharmaceutical; Israel Science Foundation; Ipsen; Array BioPharma; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Instituto de Salud Carlos III; Amgen; Novartis Pharmaceuticals Corporation; Les Laboratories Pierre Fabre","keywords":"Medicine; Oncology; Clinical trial; Internal medicine; Immunotherapy; Metastasis; Cancer","score_opus":0.17780642204238725,"score_gpt":0.5108081939300281,"score_spread":0.3330017718876408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361988864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67341995,0.11535531,0.05079271,0.11629634,0.0064572147,0.009559622,0.0000492289,0.0006750655,0.027394565],"genre_scores_gemma":[0.7610797,0.18810475,0.010345946,0.037889857,0.0007554988,0.0011083465,0.00005569245,0.000093842,0.0005663504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934338,0.0026772781,0.0020936327,0.00067026186,0.00044910156,0.0006759679],"domain_scores_gemma":[0.9938875,0.0050728656,0.00023773927,0.0003326684,0.000044962362,0.0004242814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01600995,0.0002900724,0.0020684612,0.00054110977,0.0000627172,0.000011862054,0.00029171124,0.0007814393,0.00026922193],"category_scores_gemma":[0.0011526732,0.00022351876,0.0002620879,0.0011358501,0.0008023204,0.000111660614,0.000066789005,0.0010289504,0.000026124895],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0103993,0.0012925107,0.0027877232,0.00007028287,0.0001783879,0.00018192828,0.0018216744,0.000084516556,0.0007656322,0.0011680798,0.00019043498,0.98105955],"study_design_scores_gemma":[0.038829226,0.0060831937,0.03002806,0.00031168462,0.00025997142,0.00051620987,0.0044213636,0.008778416,0.000065909415,0.0053754547,0.904776,0.00055451924],"about_ca_topic_score_codex":0.000034767992,"about_ca_topic_score_gemma":0.00020781012,"teacher_disagreement_score":0.980505,"about_ca_system_score_codex":0.00040445462,"about_ca_system_score_gemma":0.00093739067,"threshold_uncertainty_score":0.91148305},"labels":[],"label_agreement":null},{"id":"W4378530850","doi":"10.1177/17588359231177008","title":"Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Cochrane Library; Internal medicine; Oncology; Lung cancer; Biomarker; MEDLINE; Sample size determination; Systematic review; Cancer; Adjuvant therapy; Prospective cohort study; Pathological","score_opus":0.021904039043796487,"score_gpt":0.3505206216591146,"score_spread":0.32861658261531806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378530850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006698929,0.9953387,0.0004862712,0.000054313994,0.00006824399,0.0032645648,0.000081730504,0.0000046608625,0.00003163737],"genre_scores_gemma":[0.0024053182,0.995079,0.00009885544,0.0005158006,0.000021131462,0.0017200381,0.00008314789,0.000043598764,0.00003310957],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971313,0.00060878735,0.0011244534,0.0005696836,0.0002691788,0.00029663614],"domain_scores_gemma":[0.9981533,0.0005304549,0.0007334107,0.00035763046,0.000117299795,0.00010785693],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007160592,0.00039273492,0.0045475215,0.00023231033,0.000025507707,0.000007279729,0.0003187682,0.0004228382,0.00002241634],"category_scores_gemma":[0.00025615492,0.00025889202,0.00041228454,0.00073655305,0.00017181938,0.0000058105643,0.00012803794,0.00036899684,0.0000013596573],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013708205,0.00066602154,0.001349392,0.8434973,0.050979026,0.000050462957,0.00023016868,0.00015516345,0.000002196004,0.000040807896,0.000006896413,0.10288548],"study_design_scores_gemma":[0.002339205,0.0037351083,0.00038175104,0.045178358,0.91649145,0.000013635635,0.000053312182,0.00016409531,0.00001673564,0.00005103974,0.030431522,0.0011438123],"about_ca_topic_score_codex":0.000101499085,"about_ca_topic_score_gemma":0.0018509813,"teacher_disagreement_score":0.8655124,"about_ca_system_score_codex":0.00014340684,"about_ca_system_score_gemma":0.00061604526,"threshold_uncertainty_score":0.99998635},"labels":[],"label_agreement":null},{"id":"W4379383902","doi":"10.1177/17588359231175440","title":"Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Ottawa Hospital; Sinai Health System; University of Toronto; University of Alberta; University of Calgary","funders":"National Cancer Institute; Mylan; AstraZeneca Canada; Seagen; Gilead Sciences; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Clinical trial; Biomarker; Disease; Hormone receptor; Pertuzumab; Cancer; Population; Human Epidermal Growth Factor Receptor 2","score_opus":0.13996570816914805,"score_gpt":0.5367814479793399,"score_spread":0.39681573981019186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379383902","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003983862,0.9937808,0.00008090686,0.0018742908,0.0009420016,0.0025413341,0.00007117543,0.00013889889,0.00053073955],"genre_scores_gemma":[0.00014602467,0.9943541,0.00045620496,0.0006221038,0.00089276594,0.0029178194,0.00015640163,0.00021334006,0.00024122262],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917804,0.0021563962,0.0019736271,0.0012041201,0.0013703188,0.0015151621],"domain_scores_gemma":[0.99523425,0.0027782961,0.00046229752,0.00069663214,0.000080774014,0.00074772886],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029042133,0.0007944117,0.004872832,0.00082198204,0.00007898566,0.000023313924,0.00076259667,0.00080930325,0.0027249262],"category_scores_gemma":[0.00048563644,0.00057335576,0.0003494075,0.0016784094,0.00065358455,0.00020500667,0.0001562882,0.002269163,0.0001810645],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00013886298,0.00096279365,0.00030885614,0.011137751,0.00027788512,0.0033362473,0.00034821316,0.00003074787,3.8912646e-7,0.000109321954,0.000043264372,0.9833057],"study_design_scores_gemma":[0.0025870749,0.0014602459,0.00008755859,0.0261721,0.00055968715,0.00061922305,0.00025365988,0.0012610762,3.1023225e-7,0.00068160327,0.96584195,0.0004755306],"about_ca_topic_score_codex":0.00093107607,"about_ca_topic_score_gemma":0.003384941,"teacher_disagreement_score":0.9828301,"about_ca_system_score_codex":0.0065296646,"about_ca_system_score_gemma":0.008106926,"threshold_uncertainty_score":0.9996718},"labels":[],"label_agreement":null},{"id":"W4379508645","doi":"10.1177/17588359231178125","title":"Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2− early breast cancer","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Genentech; PharmaMar; Novartis Institutes for BioMedical Research; Daewoong Pharmaceutical Company; Astellas Pharma; Eisai; Seagen; Mersana Therapeutics; Mylan; Syndax Pharmaceuticals; Clovis Oncology; Astex Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; F. Hoffmann-La Roche; Amgen; Radius Health; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Exelixis; Sanofi; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Letrozole; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Anastrozole; Palbociclib; Metastatic breast cancer; Goserelin; Randomization; Cancer; Adjuvant therapy; Clinical trial; Tamoxifen; Gynecology","score_opus":0.0373529934834873,"score_gpt":0.3836976276393478,"score_spread":0.3463446341558605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379508645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980725,0.010088973,0.0010597844,0.0021966808,0.00080118305,0.0048710853,0.00011343597,0.0000717459,0.00007210241],"genre_scores_gemma":[0.96795684,0.028822115,0.00079624186,0.00072413473,0.00041012393,0.0010714,0.00008391463,0.00007604025,0.0000591705],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99580514,0.00049899664,0.0012368147,0.0006071044,0.0011874264,0.0006645039],"domain_scores_gemma":[0.9970915,0.0014662707,0.0005772582,0.0003942134,0.0002426967,0.00022809443],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082490285,0.00042523065,0.0016587125,0.00042346836,0.000050497307,0.0000052146547,0.00030994372,0.00020442388,0.00052870647],"category_scores_gemma":[0.000118714794,0.0003113406,0.00010432195,0.0010592282,0.0011171214,0.0003305318,0.000067869594,0.0005880766,0.0000022450001],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.568946,0.0025650654,0.002403034,0.00003627621,0.00020886707,0.000073261464,0.0005420698,0.00008733958,0.0004594721,0.000076562595,0.0000061898318,0.42459586],"study_design_scores_gemma":[0.9492896,0.028877662,0.008946215,0.00027061565,0.00006929176,0.00003717082,0.0002623628,0.00024374641,0.0009863175,0.0006868613,0.010014846,0.00031529603],"about_ca_topic_score_codex":0.00016801676,"about_ca_topic_score_gemma":0.00015196434,"teacher_disagreement_score":0.42428055,"about_ca_system_score_codex":0.0002576988,"about_ca_system_score_gemma":0.0009079584,"threshold_uncertainty_score":0.99993384},"labels":[],"label_agreement":null},{"id":"W4381889685","doi":"10.1177/17588359231183682","title":"Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa; Dr. H. Bliss Murphy Cancer Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Université Laval; Moncton Hospital; Université de Sherbrooke; Queen's University; Pancreas Centre (Canada)","funders":"BC Cancer Foundation","keywords":"Medicine; Colorectal cancer; Circulating tumor DNA; Disease; Oncology; Cancer; Internal medicine; Cancer research","score_opus":0.01740138278459184,"score_gpt":0.34738841161848244,"score_spread":0.3299870288338906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381889685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926634,0.002485535,0.0016153989,0.002010967,0.0002660068,0.00040752656,0.00002565351,0.000009640517,0.00051591685],"genre_scores_gemma":[0.9957611,0.0015374437,0.0009867069,0.0012524973,0.00014845938,0.0002478354,0.000021294323,0.000024868694,0.000019792895],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99851584,0.00017720716,0.0003598742,0.00031677372,0.00026613392,0.0003641561],"domain_scores_gemma":[0.9990583,0.00043671514,0.00011973161,0.00018772899,0.000044573324,0.0001529584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006273641,0.00014930702,0.00032561817,0.000058864858,0.00004068555,0.0000065712843,0.00029627993,0.000074136224,0.000090136105],"category_scores_gemma":[0.00041827667,0.00010773162,0.000049717295,0.00041028348,0.00020603984,0.000006612139,0.000111741,0.00018132568,0.0000054512384],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065503595,0.000873253,0.09304172,0.00029093388,0.0005106432,0.0019178042,0.005429098,0.14616688,0.06853002,0.0029658685,0.000194615,0.6735288],"study_design_scores_gemma":[0.054839473,0.009090388,0.45684657,0.002891006,0.0013416108,0.000690305,0.016067835,0.14066932,0.025236333,0.038181797,0.24904093,0.005104427],"about_ca_topic_score_codex":0.00009732161,"about_ca_topic_score_gemma":0.001608423,"teacher_disagreement_score":0.66842437,"about_ca_system_score_codex":0.00008624822,"about_ca_system_score_gemma":0.00067687006,"threshold_uncertainty_score":0.43931678},"labels":[],"label_agreement":null},{"id":"W4383647203","doi":"10.1177/17588359231183668","title":"Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; London Health Sciences Centre","funders":"","keywords":"SABR volatility model; Medicine; Lung cancer; Oncology; Clinical trial; Radiation therapy; Narrative review; Internal medicine; Medical physics; Intensive care medicine","score_opus":0.14720216806980715,"score_gpt":0.5244359166054591,"score_spread":0.37723374853565195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383647203","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000105971456,0.99028736,0.000040219722,0.005888887,0.00019076501,0.0032829957,0.000047696816,0.00000559609,0.000150519],"genre_scores_gemma":[0.000030755586,0.99806273,0.00034083409,0.0002887726,0.0001159402,0.0009161289,0.00019239626,0.00002359627,0.000028850181],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954771,0.001592452,0.0015982469,0.00041280087,0.00064198306,0.00027744786],"domain_scores_gemma":[0.9942387,0.004490885,0.00058410555,0.00047994682,0.00012161422,0.000084770996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005669975,0.00023630212,0.0018285724,0.00035689413,0.00004095773,0.0000046428186,0.00023547294,0.00026714403,0.00009222154],"category_scores_gemma":[0.00075913814,0.00014130956,0.00009970129,0.0012416493,0.0006987919,0.000074114854,0.00007607191,0.00062438945,0.0000011013523],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022923459,0.00073265436,0.0000456148,0.045875087,0.00019744692,0.000048388418,0.0005462608,1.5085753e-7,0.0000036059544,0.00005616391,0.00006512815,0.9522003],"study_design_scores_gemma":[0.0023254906,0.0013814629,0.00013804792,0.05861427,0.0008508029,0.00013203819,0.000284135,0.00011917036,0.00000605728,0.00009943357,0.9359373,0.000111791815],"about_ca_topic_score_codex":0.00026272587,"about_ca_topic_score_gemma":0.00038818285,"teacher_disagreement_score":0.9520885,"about_ca_system_score_codex":0.00055602717,"about_ca_system_score_gemma":0.0031380367,"threshold_uncertainty_score":0.57624364},"labels":[],"label_agreement":null},{"id":"W4383647369","doi":"10.1177/17588359231183676","title":"Clinical trial reform in the post-COVID era","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Clinical trial; Medicine; Telehealth; Pandemic; Health care; Telemedicine; Coronavirus disease 2019 (COVID-19); Pathology; Political science; Disease","score_opus":0.24283984504246986,"score_gpt":0.5987535896468035,"score_spread":0.3559137446043336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383647369","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009443825,0.9775955,0.000052595824,0.012336181,0.0024105988,0.004232876,0.000010138426,0.000079367004,0.0031882962],"genre_scores_gemma":[0.00005366006,0.97003794,0.00017746916,0.0255877,0.0026547452,0.0010208918,0.00031072326,0.00006061563,0.00009624084],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99165046,0.002300562,0.0034952457,0.00064798706,0.0011217508,0.00078397506],"domain_scores_gemma":[0.991742,0.006467825,0.00077083806,0.0006036184,0.000057518344,0.00035817595],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009996858,0.00042328925,0.0034409638,0.00050181634,0.00006276141,0.0000066002303,0.0007000116,0.0011164254,0.0006596149],"category_scores_gemma":[0.0022447552,0.00022931417,0.00041324616,0.0011486115,0.0005128819,0.000085108106,0.000103190934,0.003602791,0.00018446539],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003210626,0.0005555897,0.00007079719,0.0043599373,0.000073902964,0.0010334217,0.0002566101,2.7263502e-8,3.2225302e-9,0.0007896066,0.00017779195,0.9894717],"study_design_scores_gemma":[0.032728136,0.006116902,0.0001753687,0.0035975112,0.0004558051,0.00037063472,0.0007119826,0.00000590902,5.132627e-9,0.00086224906,0.95479137,0.00018415805],"about_ca_topic_score_codex":0.00014683508,"about_ca_topic_score_gemma":0.0017699217,"teacher_disagreement_score":0.98928756,"about_ca_system_score_codex":0.0011408536,"about_ca_system_score_gemma":0.005033107,"threshold_uncertainty_score":0.9986959},"labels":[],"label_agreement":null},{"id":"W4386137644","doi":"10.1177/17588359231192399","title":"The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Durvalumab; Atezolizumab; Chemoimmunotherapy; Oncology; Radiation therapy; Immunotherapy; Lung cancer; Internal medicine; Chemotherapy; Prophylactic cranial irradiation; Pembrolizumab; Clinical trial; Cancer","score_opus":0.05325617056729078,"score_gpt":0.5120078415180879,"score_spread":0.4587516709507971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386137644","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000515605,0.9935106,0.000048821068,0.0013237365,0.00026224795,0.0033355912,0.000035259,0.00001672768,0.00095141],"genre_scores_gemma":[0.00067300507,0.9967161,0.0001361076,0.00055740954,0.00016468193,0.0015401421,0.000011494759,0.000076571036,0.00012450799],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930871,0.0028816562,0.0017451562,0.00051568146,0.0009771906,0.00079318555],"domain_scores_gemma":[0.98601687,0.0121320505,0.0009837778,0.0006171393,0.00016898382,0.00008118166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004842172,0.00046376535,0.0032722796,0.00044216999,0.000072280796,0.000007172864,0.001056525,0.00048121886,0.00010959148],"category_scores_gemma":[0.0006292872,0.00024267536,0.0002941896,0.0015690365,0.0014659545,0.000057920322,0.00015288635,0.0021993378,0.0000021259507],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057766825,0.00026411487,0.0012687651,0.007833201,0.00039871383,0.00015537742,0.0057515395,0.000014524446,0.0000132398145,0.00022002797,0.000013915324,0.9834889],"study_design_scores_gemma":[0.0023309698,0.0008002187,0.00032812767,0.021857077,0.00024369266,0.000031427615,0.007221212,0.00030878664,0.000032302087,0.000727561,0.965844,0.00027463547],"about_ca_topic_score_codex":0.00044581605,"about_ca_topic_score_gemma":0.0030690788,"teacher_disagreement_score":0.98321426,"about_ca_system_score_codex":0.0011363574,"about_ca_system_score_gemma":0.003210095,"threshold_uncertainty_score":0.98960143},"labels":[],"label_agreement":null},{"id":"W4387133870","doi":"10.1177/17588359231198943","title":"Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sarcoma; Proportional hazards model; Radiation therapy; Internal medicine; Soft tissue sarcoma; Osteosarcoma; Angiosarcoma; Oncology; Bone Sarcoma; Chemotherapy; Retrospective cohort study; Multivariate analysis; Database; Surgery; Pathology","score_opus":0.041873041809638155,"score_gpt":0.41402758277280705,"score_spread":0.3721545409631689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387133870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98932505,0.00498476,0.000017628367,0.0042525996,0.00036727005,0.0007360928,0.000006268467,0.000057191137,0.00025315047],"genre_scores_gemma":[0.9863047,0.011842911,0.000078573124,0.0014716999,0.00007841672,0.0001637669,0.000016715469,0.00002038293,0.000022809856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978987,0.0002676438,0.00071555923,0.00031817882,0.0004823112,0.0003175909],"domain_scores_gemma":[0.9973724,0.0019286794,0.00019146023,0.00026323364,0.00004289683,0.00020132809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089940283,0.00018340226,0.00094780995,0.00030796195,0.000043493736,0.0000033216768,0.00012827177,0.00018943773,0.00013013334],"category_scores_gemma":[0.00039676458,0.00013417132,0.00008320212,0.00055092404,0.0002497634,0.000052298303,0.000060449966,0.00032420544,0.000013385371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011145323,0.0012261303,0.5352906,0.00001986833,0.000111200236,0.00027600993,0.0004270954,1.8349266e-7,0.000012039667,0.00012879776,0.000005872115,0.46239072],"study_design_scores_gemma":[0.0061228108,0.002354621,0.98181474,0.000052205854,0.00017922546,0.000033820696,0.0009491879,0.00016975169,0.000029637586,0.00074315676,0.0074430015,0.00010785744],"about_ca_topic_score_codex":0.000063418134,"about_ca_topic_score_gemma":0.00023161074,"teacher_disagreement_score":0.46228287,"about_ca_system_score_codex":0.000080099475,"about_ca_system_score_gemma":0.00023162707,"threshold_uncertainty_score":0.54713476},"labels":[],"label_agreement":null},{"id":"W4391325299","doi":"10.1177/17588359231220511","title":"The role of aberrant DNA methylation in cancer initiation and clinical impacts","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Health and Medical Research Council; National Cancer Institute; National Institutes of Health; Sierra Oncology; Swiss Cancer Research Foundation; Eisai; BeiGene; Clovis Oncology; AstraZeneca","keywords":"DNA methylation; Epigenetics; Methylation; Cancer research; DNA repair; Biology; Cancer epigenetics; MSH2; Context (archaeology); MLH1; DNA mismatch repair; Medicine; Genetics; Gene; Gene expression","score_opus":0.022225462354696527,"score_gpt":0.42088266976538263,"score_spread":0.3986572074106861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391325299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7516824,0.2448303,0.0011100199,0.00091139384,0.00037796595,0.00013794677,0.0000022089473,0.000004228469,0.00094352505],"genre_scores_gemma":[0.85790265,0.14169419,0.00009202648,0.00012617835,0.00014018812,0.00002020356,0.000007828952,0.000007327902,0.0000094146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876964,0.00030584168,0.0004293524,0.00019404617,0.00014928977,0.00015181722],"domain_scores_gemma":[0.99927586,0.00046547205,0.00007810289,0.00010020173,0.000028388191,0.000051973264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014862628,0.00007547583,0.00016182462,0.00004694037,0.00002298306,0.000006422415,0.000094743045,0.00023150835,0.000017566748],"category_scores_gemma":[0.00026694319,0.000052328603,0.000033323948,0.00012416115,0.0002287885,0.000008047384,0.00003867869,0.00019390351,7.4390175e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010717261,0.000055903933,0.014568619,0.000015082936,0.000019432198,0.000002876007,0.000114769915,0.000040265415,0.02078411,0.0010647305,0.0000015835376,0.9632254],"study_design_scores_gemma":[0.0024661329,0.002135672,0.14392386,0.00024650386,0.000068130175,0.000009493879,0.00053245365,0.01646689,0.0686502,0.07818844,0.6869758,0.00033643618],"about_ca_topic_score_codex":0.000027315771,"about_ca_topic_score_gemma":0.0015757468,"teacher_disagreement_score":0.962889,"about_ca_system_score_codex":0.00003262118,"about_ca_system_score_gemma":0.00023538702,"threshold_uncertainty_score":0.21338984},"labels":[],"label_agreement":null},{"id":"W4394850223","doi":"10.1177/17588359241247008","title":"Real-world experience supporting the role of oncologic resection and adjuvant chemotherapy in biliary tract cancers","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Hazard ratio; Gallbladder cancer; Internal medicine; Cohort; Capecitabine; Cancer; Confidence interval; Population; Surgery; Intrahepatic Cholangiocarcinoma; Chemotherapy; Retrospective cohort study; Oncology; Gastroenterology; Colorectal cancer","score_opus":0.023284938017677767,"score_gpt":0.3965308868266167,"score_spread":0.3732459488089389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394850223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8806041,0.100153856,0.00003434012,0.0072145937,0.00046972753,0.00045170853,0.0000013204245,0.000041313786,0.011029047],"genre_scores_gemma":[0.957522,0.040768616,0.00009713049,0.0012042435,0.00018094908,0.00013184597,0.0000018182199,0.000014361834,0.00007907866],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983417,0.00015430216,0.00051422394,0.00033635448,0.00032974983,0.00032366917],"domain_scores_gemma":[0.9987843,0.00085059967,0.00009599823,0.0001616379,0.000026138025,0.000081338694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088988664,0.00014753996,0.00051299186,0.00018371934,0.000041435043,0.0000052963264,0.0001337871,0.00013314286,0.00021082949],"category_scores_gemma":[0.00011099338,0.00009151714,0.000057619585,0.00055184454,0.00066585955,0.00010857957,0.000045695902,0.000566212,0.000001291833],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005756466,0.00013404433,0.16932315,0.000095224656,0.000033666176,0.00022999672,0.008536525,0.00000879548,0.00092573767,0.00059890986,0.000021242844,0.8195171],"study_design_scores_gemma":[0.0046898928,0.0035126372,0.6458582,0.0011406172,0.00011700727,0.00041353249,0.025130637,0.006373837,0.0026404937,0.010944908,0.2988199,0.00035833046],"about_ca_topic_score_codex":0.00075705006,"about_ca_topic_score_gemma":0.0062952447,"teacher_disagreement_score":0.81915873,"about_ca_system_score_codex":0.0005256972,"about_ca_system_score_gemma":0.0005713083,"threshold_uncertainty_score":0.37319607},"labels":[],"label_agreement":null},{"id":"W4396863343","doi":"10.1177/17588359241250158","title":"Clinical activity of pembrolizumab in refractory <i>MDM2</i> -amplified advanced intimal sarcomas","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Deciphera Pharmaceuticals; Iterion Therapeutics; Karyopharm Therapeutics; Amgen; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb; Symphogen; GlaxoSmithKline","keywords":"Pembrolizumab; Medicine; Sarcoma; Tumor microenvironment; Refractory (planetary science); Oncology; Soft tissue sarcoma; Internal medicine; Immunotherapy; Chemotherapy; Pathology; Cancer research; Cancer","score_opus":0.04223307785315796,"score_gpt":0.44233554916761947,"score_spread":0.4001024713144615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396863343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9010558,0.08235445,0.00057762285,0.0055671274,0.0012766125,0.00066079176,0.0000063201724,0.000091588576,0.008409702],"genre_scores_gemma":[0.972438,0.024403391,0.0010159657,0.0017364732,0.00018861736,0.00012574358,0.000008716385,0.000032196476,0.00005089199],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969711,0.0004684546,0.0009710197,0.00057095103,0.0005582084,0.00046027862],"domain_scores_gemma":[0.9961456,0.0030678257,0.00014013125,0.0003653329,0.000043134132,0.00023794029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011945775,0.00024798763,0.0011504934,0.00026648826,0.000020029127,0.000004724247,0.00021376756,0.0004454834,0.00052197336],"category_scores_gemma":[0.00041045126,0.0001891582,0.00020723748,0.00047897612,0.0006172464,0.00017557491,0.00009084567,0.0011267454,0.00003556554],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002065912,0.0035640928,0.050044112,0.00017125426,0.00009100193,0.0017541196,0.00016450272,0.000007661745,0.00029365264,0.0018531308,0.000039105616,0.9399515],"study_design_scores_gemma":[0.019861506,0.0063385046,0.27865493,0.0017275991,0.00024203966,0.00045546298,0.0002803834,0.0021546646,0.00096244033,0.007115459,0.68176144,0.00044554396],"about_ca_topic_score_codex":0.000030295741,"about_ca_topic_score_gemma":0.00021206828,"teacher_disagreement_score":0.93950593,"about_ca_system_score_codex":0.00043300807,"about_ca_system_score_gemma":0.0008484734,"threshold_uncertainty_score":0.7713648},"labels":[],"label_agreement":null},{"id":"W4399614669","doi":"10.1177/17588359241255174","title":"PARP inhibitors in non-ovarian gynecologic cancers","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Ovarian cancer; Context (archaeology); Olaparib; Oncology; PARP inhibitor; Endometrial cancer; Internal medicine; Poly ADP ribose polymerase; Cancer research; Cancer; Polymerase; Biology; Gene","score_opus":0.021426977265556247,"score_gpt":0.39641454717827285,"score_spread":0.3749875699127166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399614669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38020033,0.26033613,0.013744721,0.11585811,0.022316765,0.0045886184,0.00003226774,0.001079297,0.20184374],"genre_scores_gemma":[0.9684249,0.017396573,0.00076299417,0.011876685,0.00076616835,0.00042554148,0.000013869795,0.000046648012,0.00028661205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969808,0.000262633,0.00081455894,0.0006239339,0.00062744005,0.0006906221],"domain_scores_gemma":[0.9981844,0.0011065826,0.00008680132,0.0002917922,0.00003880988,0.0002916237],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013368351,0.00028181518,0.0007676254,0.00045701384,0.00003955574,0.000012611622,0.00025370475,0.00055357034,0.003381009],"category_scores_gemma":[0.00019843213,0.00023076725,0.000113288566,0.0010597776,0.00063464855,0.00021038172,0.000054879893,0.0013437646,0.00015462462],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061013806,0.00032509805,0.007480028,0.00020645358,0.00006481138,0.0030141599,0.001054775,0.00018056869,0.0005674387,0.003346463,0.00068252685,0.98246753],"study_design_scores_gemma":[0.0072540897,0.0017738342,0.007938029,0.0013222962,0.000052674288,0.0004135005,0.00064114906,0.005960372,0.0005872607,0.01886968,0.9547783,0.0004087985],"about_ca_topic_score_codex":0.000102320904,"about_ca_topic_score_gemma":0.0010688012,"teacher_disagreement_score":0.98205876,"about_ca_system_score_codex":0.0025589971,"about_ca_system_score_gemma":0.0019436738,"threshold_uncertainty_score":0.99753004},"labels":[],"label_agreement":null},{"id":"W4401261376","doi":"10.1177/17588359241266179","title":"Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada","year":2024,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University Health Centre; University of Ottawa; Université Laval; Centre hospitalier universitaire de Québec; St. Michael's Hospital; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Mount Sinai Hospital; Vancouver General Hospital; University of Calgary; University of Alberta; Ottawa Hospital; University Health Network; University of Toronto; University of British Columbia; Baker Hughes (Canada)","funders":"","keywords":"GiST; Medicine; Imatinib mesylate; Family medicine; Imatinib; Pathology; Internal medicine; Stromal cell","score_opus":0.06216501679158278,"score_gpt":0.4649279505218246,"score_spread":0.40276293373024186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401261376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006105724,0.9809421,0.000026187192,0.015331577,0.00052787305,0.0021339653,0.00023816344,0.000016517759,0.00072256546],"genre_scores_gemma":[0.000816097,0.99504095,0.0015433588,0.0009938147,0.0001243914,0.0007393372,0.00030264867,0.000042999367,0.00039639385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971978,0.00022688275,0.0007495207,0.000557207,0.0003547444,0.0009138246],"domain_scores_gemma":[0.99788725,0.0011319793,0.00011513407,0.00023650996,0.000038950442,0.0005901955],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055864174,0.00035605748,0.0014759143,0.00018367464,0.0000722028,0.00001492829,0.00019376626,0.0001942385,0.00015380162],"category_scores_gemma":[0.00021894884,0.00025830898,0.0001014952,0.00034407226,0.00038135366,0.000022263212,0.00009773016,0.00082097144,0.000015488955],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000723085,0.00016098826,0.000070046546,0.0070217256,0.00020261489,0.0061420114,0.00003391848,2.3316056e-7,7.055184e-9,0.0011211009,0.0010291857,0.9841459],"study_design_scores_gemma":[0.0019128132,0.0005204121,0.00007087538,0.009841022,0.00037786347,0.00074666284,0.00030691858,0.00003148168,7.4100555e-8,0.00094403094,0.98508155,0.0001662951],"about_ca_topic_score_codex":0.31213653,"about_ca_topic_score_gemma":0.9738346,"teacher_disagreement_score":0.98405236,"about_ca_system_score_codex":0.002837702,"about_ca_system_score_gemma":0.004146159,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W4402335895","doi":"10.1177/17588359241271913","title":"HER2 becomes a novel survival biomarker for gastric cancer patients: a pooled analysis","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Science Foundation of Hubei Province","keywords":"Medicine; Biomarker; Cancer; Oncology; Internal medicine; Trastuzumab; Breast cancer","score_opus":0.031961686564817036,"score_gpt":0.39643225979441893,"score_spread":0.3644705732296019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402335895","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25831178,0.1643447,0.43469557,0.103817515,0.015738996,0.0064370027,0.00025528358,0.0009415635,0.015457613],"genre_scores_gemma":[0.9829082,0.0073924484,0.0016870932,0.005553609,0.00044322628,0.00056940096,0.0001056582,0.000046326913,0.0012940735],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977471,0.00007513515,0.0005747608,0.00049622834,0.00058442686,0.00052233646],"domain_scores_gemma":[0.99847853,0.0009382857,0.00009494774,0.00020348778,0.00008528222,0.00019943871],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068722083,0.00023672925,0.000864199,0.00071200955,0.00004229127,0.000017442562,0.00021783439,0.00019576428,0.0015514311],"category_scores_gemma":[0.00018701388,0.00017634717,0.00031407585,0.0019440402,0.00020183131,0.0001345058,0.00007012425,0.00030840197,0.000011562207],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066137966,0.00062789716,0.12857793,0.00026607292,0.002288008,0.00006242066,0.00017186593,0.000035102825,0.00002104627,0.0012269502,0.00038323144,0.8656781],"study_design_scores_gemma":[0.0081419,0.0011996117,0.18970127,0.00019803685,0.0046173274,0.000010672007,0.00027068882,0.01646231,0.000007364754,0.0009496109,0.77814144,0.00029974297],"about_ca_topic_score_codex":0.000091674134,"about_ca_topic_score_gemma":0.0010393352,"teacher_disagreement_score":0.8653783,"about_ca_system_score_codex":0.00052383833,"about_ca_system_score_gemma":0.00040464895,"threshold_uncertainty_score":0.9993613},"labels":[],"label_agreement":null},{"id":"W4402938149","doi":"10.1177/17588359241277656","title":"Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McGill University Health Centre","funders":"Eisai; Clovis Oncology; Incyte; Novocure; Regeneron Pharmaceuticals; Seagen; Gilead Sciences; Genentech; Mersana Therapeutics; AstraZeneca; Pfizer","keywords":"Medicine; Placebo; Adverse effect; Common Terminology Criteria for Adverse Events; Internal medicine; Endometrial cancer; Randomized controlled trial; Population; Carboplatin; Phases of clinical research; Chemotherapy; Oncology; Surgery; Cancer; Pathology","score_opus":0.01383054762002973,"score_gpt":0.35803513108909374,"score_spread":0.344204583469064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402938149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9583752,0.020384261,0.00066821644,0.0024027212,0.0014777955,0.015343511,0.00003086244,0.00005535264,0.0012620898],"genre_scores_gemma":[0.9776575,0.017409455,0.0004656772,0.0007948513,0.00019755967,0.0032829628,0.000077844255,0.00005212825,0.00006202421],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99447465,0.0009864501,0.0019753026,0.0007077704,0.0012223436,0.0006334629],"domain_scores_gemma":[0.99378765,0.0051996163,0.00044529705,0.0002537109,0.00011163319,0.00020208901],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024758682,0.0004594821,0.003608475,0.0012757815,0.000025239931,0.0000095836995,0.00023949327,0.00035549983,0.0009854379],"category_scores_gemma":[0.0008342499,0.00026302956,0.00017694377,0.0027137224,0.00050837203,0.00027854295,0.000041189018,0.0010022839,0.0000018849173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5623986,0.00522412,0.0012646331,0.00013426474,0.00021005415,0.00016977193,0.0005370014,0.000046931997,0.000007302435,0.000089914975,9.4529764e-7,0.42991644],"study_design_scores_gemma":[0.973422,0.019385288,0.0014466986,0.0016198691,0.00022589498,0.000006871623,0.00013125586,0.0006606193,0.000044442284,0.00052372477,0.0022609215,0.00027242475],"about_ca_topic_score_codex":0.00019912272,"about_ca_topic_score_gemma":0.0023519131,"teacher_disagreement_score":0.42964402,"about_ca_system_score_codex":0.0020149418,"about_ca_system_score_gemma":0.0016914125,"threshold_uncertainty_score":0.9999822},"labels":[],"label_agreement":null},{"id":"W4403509921","doi":"10.1177/17588359241289200","title":"Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Bioinformatics and Genomic Networks","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; Canadian Institutes of Health Research; Fondation ARC pour la Recherche sur le Cancer; FP7 Capacities; Pfizer; European Commission; Novartis Pharmaceuticals Corporation; Canadian Cancer Society; Eli Lilly and Company","keywords":"Medicine; Identification (biology); Transcriptome; Gene; Key (lock); Computational biology; Correlation; Oncology; Internal medicine; Cancer research; Bioinformatics; Gene expression; Biology; Genetics","score_opus":0.008267509903340301,"score_gpt":0.28174128653232877,"score_spread":0.2734737766289885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403509921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90029633,0.0036751155,0.095104,0.00013087082,0.00027858594,0.00040564738,0.000019176621,0.000005075496,0.00008520615],"genre_scores_gemma":[0.9986133,0.0004880894,0.0006297896,0.000086407286,0.000056121487,0.00001533517,0.000096757685,0.000011214079,0.000002987483],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99876153,0.00013119029,0.00054023013,0.00017465884,0.00019096253,0.00020139874],"domain_scores_gemma":[0.9994843,0.0001818062,0.00014474893,0.000106066465,0.00003096964,0.00005209309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005359804,0.0001089963,0.00029346862,0.00006424628,0.000013645752,0.0000043117234,0.00009079885,0.00012660722,0.0000065181844],"category_scores_gemma":[0.000034039233,0.00008638668,0.000028373493,0.00015558474,0.00021362455,0.000009074063,0.000015466732,0.00015611085,2.893194e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014954264,0.00048832747,0.39062306,0.00053077,0.0001501724,0.0000101391515,0.0006147505,0.05327245,0.0008161321,0.0015773042,0.000008217875,0.55041325],"study_design_scores_gemma":[0.009760909,0.008037543,0.5312353,0.0012725989,0.00033022877,0.000007998436,0.00035380214,0.43310696,0.0022532663,0.007301142,0.0056574377,0.0006828384],"about_ca_topic_score_codex":0.0000030687725,"about_ca_topic_score_gemma":0.000062790234,"teacher_disagreement_score":0.5497304,"about_ca_system_score_codex":0.000026839542,"about_ca_system_score_gemma":0.00016993532,"threshold_uncertainty_score":0.35227466},"labels":[],"label_agreement":null},{"id":"W4405764199","doi":"10.1177/17588359241308466","title":"Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Oncology; Internal medicine; Epidermal growth factor receptor; Lung cancer; Cancer research; ROS1; Crizotinib; Stage (stratigraphy); Targeted therapy; Cancer; Adenocarcinoma; Biology","score_opus":0.015666433802951872,"score_gpt":0.41040352604992875,"score_spread":0.3947370922469769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405764199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96067923,0.015689418,0.005390422,0.005055819,0.00030252358,0.00072646904,0.00004999762,0.00008606884,0.012020031],"genre_scores_gemma":[0.99626464,0.0009225866,0.0010272379,0.0005011527,0.000021765656,0.00011176364,0.00007556049,0.000014929953,0.0010603596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864143,0.00010339824,0.00038119397,0.00026309208,0.00037331358,0.00023759456],"domain_scores_gemma":[0.9990463,0.0005607221,0.000060691298,0.00017377158,0.000056912493,0.000101560465],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021689717,0.00012415215,0.0006229831,0.00060280185,0.000023409233,0.0000050015983,0.00009153807,0.00012637353,0.0012077455],"category_scores_gemma":[0.00007362752,0.000080261605,0.000083619845,0.0016831845,0.0002711948,0.00013671053,0.000017788063,0.00029488743,0.0000072719276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059519085,0.0011207297,0.7863328,0.00016135856,0.0034991927,0.0016475937,0.005754695,0.0017307897,0.0000997919,0.004358573,0.000011605413,0.1946877],"study_design_scores_gemma":[0.008428088,0.0023411906,0.8820061,0.00053239084,0.004471281,0.0000312827,0.0023380038,0.012790122,0.00013950355,0.0016517409,0.084976844,0.00029342118],"about_ca_topic_score_codex":0.00025427545,"about_ca_topic_score_gemma":0.0026257986,"teacher_disagreement_score":0.19439428,"about_ca_system_score_codex":0.00029143938,"about_ca_system_score_gemma":0.00065366674,"threshold_uncertainty_score":0.9997053},"labels":[],"label_agreement":null},{"id":"W4406124968","doi":"10.1177/17588359241308784","title":"The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; William Osler Health System; Queen Elizabeth II Health Sciences Centre; University of Ottawa; Dalhousie University; University of Toronto; University of Manitoba; Juravinski Cancer Centre; University of British Columbia; University Health Network; Ottawa Hospital; CancerCare Manitoba; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Eli Lilly Canada; Bayer Canada; Pfizer Canada; Novartis Pharmaceuticals Canada; Bristol-Myers Squibb Canada; EMD Serono; Astellas Pharma; Genentech; AstraZeneca Canada; Amgen Canada; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Epidermal growth factor receptor; KRAS; Anaplastic lymphoma kinase; Medicine; Crizotinib; Cancer research; Lung cancer; ROS1; Erlotinib; Clinical trial; Biomarker; EGFR inhibitors; Cancer; Targeted therapy; Oncology; Internal medicine; Biology; Adenocarcinoma; Colorectal cancer","score_opus":0.022030025022744974,"score_gpt":0.4331020654722201,"score_spread":0.4110720404494751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406124968","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012760414,0.9870696,0.00064180803,0.00074195646,0.0009057218,0.0022471584,0.000036951475,0.00002529083,0.008203927],"genre_scores_gemma":[0.000706977,0.9948339,0.0011923623,0.0005596105,0.00017051624,0.0014773794,0.000047513764,0.00005115859,0.0009605878],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99675965,0.000284564,0.0013695331,0.0005435854,0.00046830627,0.0005743804],"domain_scores_gemma":[0.995671,0.0029188162,0.0006614895,0.00045823748,0.00014865134,0.00014184194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006466199,0.00047967996,0.0025912724,0.0003221767,0.000088517205,0.000009965563,0.00055575126,0.0005876872,0.00019116505],"category_scores_gemma":[0.00020292857,0.00028798435,0.00032416277,0.00075315783,0.00035668528,0.000080594386,0.00012120424,0.0009448369,0.000002231163],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012408168,0.00064552116,0.0010082256,0.006917362,0.0004604179,0.00007067544,0.0007249557,0.000039153234,0.000004556072,0.00016077791,0.000041235922,0.989803],"study_design_scores_gemma":[0.006372998,0.0004346048,0.00013524407,0.025299331,0.0015897452,0.00002679136,0.00059260003,0.00047871587,0.0000031529096,0.000061033938,0.9647338,0.0002720091],"about_ca_topic_score_codex":0.00006495784,"about_ca_topic_score_gemma":0.0017272831,"teacher_disagreement_score":0.98953104,"about_ca_system_score_codex":0.00083044183,"about_ca_system_score_gemma":0.006057138,"threshold_uncertainty_score":0.9999572},"labels":[],"label_agreement":null},{"id":"W4407230737","doi":"10.1177/17588359251316176","title":"TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Astellas Pharma; Daiichi-Sankyo; Natera; Puma Biotechnology; Syndax Pharmaceuticals; Chugai Pharmaceutical; Nihon Medi-Physics; Eisai; Jazz Pharmaceuticals; Incyte; Taiho Pharmaceutical; Spectrum Pharmaceuticals; Boston Scientific Corporation; Gilead Sciences; Exelixis; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Pembrolizumab; Internal medicine; Breast cancer; Chemotherapy; Clinical endpoint; Oncology; Adjuvant; Triple-negative breast cancer; Cancer; Clinical trial; Immunotherapy","score_opus":0.01792386089167593,"score_gpt":0.41262272750791656,"score_spread":0.39469886661624065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407230737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817506,0.006836482,0.00027074805,0.0009770663,0.0006683488,0.007989002,0.0009069059,0.00004410062,0.00055673247],"genre_scores_gemma":[0.9936927,0.0037218987,0.00020455463,0.0001885561,0.00005750541,0.0016468219,0.00013905497,0.00006997171,0.00027896947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992521,0.0016982466,0.0018979016,0.00097141153,0.0019602485,0.00095120264],"domain_scores_gemma":[0.9952405,0.002310305,0.00068199274,0.00079082174,0.0005787491,0.00039760096],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001042743,0.00062815327,0.0041743694,0.00058173295,0.00010016069,0.0000116196225,0.0005845389,0.00039896206,0.001128817],"category_scores_gemma":[0.00055367907,0.00041128302,0.00020725853,0.0014126974,0.0014608823,0.0002019363,0.00017066528,0.00089294586,0.0000020287264],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6742165,0.006190035,0.014797596,0.00029243357,0.0009429751,0.00031248428,0.0058389637,0.00006191218,0.0000173041,0.000039686627,0.000023233897,0.2972669],"study_design_scores_gemma":[0.9244431,0.04980676,0.00576666,0.0013801516,0.00083496235,0.000010089713,0.013224253,0.0006327107,0.00039658014,0.000062250816,0.00305905,0.00038341523],"about_ca_topic_score_codex":0.0058664796,"about_ca_topic_score_gemma":0.032550905,"teacher_disagreement_score":0.29688346,"about_ca_system_score_codex":0.004106665,"about_ca_system_score_gemma":0.0061634886,"threshold_uncertainty_score":0.9998339},"labels":[],"label_agreement":null},{"id":"W4408459343","doi":"10.1177/17588359251323985","title":"Immunotherapy in advanced, <i>KRAS</i> G12C-mutant non-small-cell lung cancer: current strategies and future directions","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"KRAS; Medicine; Cancer research; Blockade; Lung cancer; Cancer; Mutation; Immunotherapy; Mutant; Selumetinib; Oncology; Internal medicine; Biology; Colorectal cancer; Receptor","score_opus":0.016739884954371346,"score_gpt":0.4375702361328022,"score_spread":0.4208303511784309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408459343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059139038,0.988282,0.00028424733,0.0010537454,0.0026240963,0.002461515,0.000046955698,0.000058794525,0.0051294775],"genre_scores_gemma":[0.000059294493,0.99555004,0.00037087052,0.0006590605,0.0005822223,0.0024170605,0.00009667712,0.000057164478,0.00020762082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968831,0.0003047944,0.0010774019,0.0007657463,0.00036662823,0.0006023603],"domain_scores_gemma":[0.9982765,0.000687314,0.00036369634,0.00038701558,0.00006951808,0.00021600879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033638856,0.00063998817,0.0026841841,0.0004814749,0.00010758287,0.000024496847,0.00028769713,0.0006567,0.00025144502],"category_scores_gemma":[0.00002274081,0.00045896013,0.0002562008,0.0009276437,0.0002957831,0.00020175628,0.00007595059,0.0015373591,0.0000037776758],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009261035,0.00069229916,0.00017672566,0.011896993,0.00023788254,0.00014709293,0.000547697,0.000004985942,9.0363244e-7,0.00042477302,0.000018944243,0.9857591],"study_design_scores_gemma":[0.0039822296,0.00032020343,0.000077071716,0.016786505,0.0011810038,0.000080521815,0.0006537507,0.000032376563,7.8416554e-7,0.0003095963,0.97623086,0.0003450794],"about_ca_topic_score_codex":0.000087087865,"about_ca_topic_score_gemma":0.00090606854,"teacher_disagreement_score":0.985414,"about_ca_system_score_codex":0.0013980039,"about_ca_system_score_gemma":0.006854212,"threshold_uncertainty_score":0.9997862},"labels":[],"label_agreement":null},{"id":"W4408682588","doi":"10.1177/17588359251326710","title":"Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Novartis Pharmaceuticals Canada; Genentech; Astellas Pharma; Seagen; University of Toronto; Genomic Health; F. Hoffmann-La Roche; Purdue University; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Novartis; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Adverse effect; Discontinuation; Breast cancer; Adjuvant; Oncology; Clinical trial; Disease; Internal medicine; Cancer; Intensive care medicine; Quality of life (healthcare); Metastatic breast cancer","score_opus":0.05930661329680937,"score_gpt":0.42576301221026475,"score_spread":0.3664563989134554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408682588","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005392155,0.9938533,0.00007988824,0.0015961966,0.000977689,0.0024041072,0.00005455545,0.00003956714,0.0004555217],"genre_scores_gemma":[0.000687691,0.9916304,0.0002888541,0.0058110515,0.00035586715,0.0009114409,0.000031736952,0.00008998815,0.0001930071],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99452984,0.00094681873,0.0019262871,0.000813352,0.0011423,0.00064142357],"domain_scores_gemma":[0.9936411,0.0041940575,0.0009125696,0.0008340865,0.0002154743,0.00020275358],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004990231,0.0007259228,0.0036074363,0.0005865451,0.000053137246,0.000008199877,0.0006364249,0.0008811424,0.0003737802],"category_scores_gemma":[0.00037127014,0.0003882208,0.00029392185,0.0012620233,0.0011783872,0.00021616924,0.00014727538,0.0019451429,0.000009560161],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001577558,0.0009730632,0.002369007,0.0019310003,0.00024803422,0.000081761405,0.00035408436,0.000011029917,7.448667e-8,0.00033294817,0.00006504626,0.99205637],"study_design_scores_gemma":[0.0038256499,0.001179428,0.002106447,0.04917484,0.00025963358,0.00002052343,0.00006124278,0.0000048397987,9.0121745e-7,0.00016762664,0.9428617,0.0003372164],"about_ca_topic_score_codex":0.0001601554,"about_ca_topic_score_gemma":0.0005527445,"teacher_disagreement_score":0.9917192,"about_ca_system_score_codex":0.0013548278,"about_ca_system_score_gemma":0.0029006836,"threshold_uncertainty_score":0.99985695},"labels":[],"label_agreement":null},{"id":"W4409528322","doi":"10.1177/17588359251327992","title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Chugai Pharmaceutical; Samsung; Aptitude Health; Astellas Pharma; Eisai; Relay Therapeutics; Seagen; Silverback Therapeutics; Daewoong Pharmaceutical Company; AstraZeneca España; Puma Biotechnology; Genentech; Veracyte; Mersana Therapeutics; Menarini Silicon Biosystems; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer; HCA Healthcare; Les Laboratories Pierre Fabre; G1 Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Durvalumab; Gemcitabine; Clinical endpoint; Internal medicine; Oncology; Carboplatin; Chemotherapy; Clinical trial; Cancer; Immunotherapy; Cisplatin","score_opus":0.031952928587810535,"score_gpt":0.43753937024167455,"score_spread":0.40558644165386404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409528322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814369,0.0019822677,0.002463116,0.002405763,0.0006248378,0.010373609,0.00005618976,0.00005862646,0.00059868937],"genre_scores_gemma":[0.9916603,0.0032125828,0.0010143465,0.0010758158,0.00007546773,0.00251456,0.00002778434,0.000070486785,0.00034863752],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992877,0.0018915392,0.0015189461,0.00091695576,0.0019000008,0.00089557417],"domain_scores_gemma":[0.9952764,0.002699392,0.0004925244,0.000636412,0.0005379254,0.00035734635],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017543855,0.00057127787,0.0034545395,0.0006037645,0.000091706584,0.0000152695,0.0005811885,0.00023204953,0.002413876],"category_scores_gemma":[0.0006017924,0.0003093073,0.000090722824,0.0019371354,0.0015444166,0.00023149916,0.000112956295,0.001307926,0.0000034317593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71285236,0.008599777,0.0068035326,0.0002867294,0.0010078498,0.00022796438,0.0026701135,0.00013897638,0.00000275156,0.00005858612,0.000018664035,0.2673327],"study_design_scores_gemma":[0.95106405,0.03041961,0.005763474,0.0019555495,0.0006645918,0.00004640246,0.0037737342,0.0046166815,0.000041402687,0.000111340545,0.0011727194,0.0003704306],"about_ca_topic_score_codex":0.002168591,"about_ca_topic_score_gemma":0.015469222,"teacher_disagreement_score":0.2669623,"about_ca_system_score_codex":0.002055371,"about_ca_system_score_gemma":0.008274933,"threshold_uncertainty_score":0.9999359},"labels":[],"label_agreement":null},{"id":"W4410212347","doi":"10.1177/17588359251332154","title":"Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agricultural Research Institute of Ontario; McMaster University; University of Alberta; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"Debiopharm","keywords":"Avelumab; Medicine; Lung cancer; Tolerability; Internal medicine; Oncology; Adverse effect; Cancer; Response Evaluation Criteria in Solid Tumors; Nivolumab; Toxicity; Phases of clinical research; Immunotherapy","score_opus":0.029801408251035926,"score_gpt":0.418773363259961,"score_spread":0.38897195500892506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410212347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611352,0.024461783,0.011519119,0.00024113887,0.00028428645,0.002194992,0.000012198826,0.000014282655,0.00013700663],"genre_scores_gemma":[0.97534865,0.021409845,0.0019641528,0.00055460713,0.000051251685,0.00046080907,0.00012479226,0.000034215125,0.000051648054],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99680763,0.00067638414,0.00080010283,0.0009703987,0.00026583008,0.00047967656],"domain_scores_gemma":[0.9988062,0.0002412127,0.00025355708,0.00045061376,0.00006754135,0.00018088664],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089465757,0.00037713844,0.00095980515,0.0002369617,0.00009804205,0.000022298946,0.00051574,0.0003315254,0.00003822563],"category_scores_gemma":[0.00007200253,0.00030194985,0.000031313906,0.0004925991,0.00020908104,0.000058725178,0.00028426552,0.00035996156,4.0769245e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04647457,0.0068099173,0.0029640165,0.00007169067,0.0001279057,0.0002822699,0.0015807339,0.005246558,0.28472948,0.000017196506,0.0000033599615,0.6516923],"study_design_scores_gemma":[0.7450006,0.022936901,0.042307917,0.0021053685,0.0006229084,0.000028010414,0.01369406,0.11981908,0.042471454,0.0007030824,0.008116458,0.0021941892],"about_ca_topic_score_codex":0.00022456356,"about_ca_topic_score_gemma":0.009392157,"teacher_disagreement_score":0.698526,"about_ca_system_score_codex":0.00024369212,"about_ca_system_score_gemma":0.00092878763,"threshold_uncertainty_score":0.99994326},"labels":[],"label_agreement":null},{"id":"W4410743176","doi":"10.1177/17588359251339919","title":"Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sinai Health System; CancerCare Manitoba; Mount Sinai Hospital; University of British Columbia; University of Toronto; Women's College Hospital; University of Manitoba; BC Cancer Agency","funders":"Eisai Canada","keywords":"Medicine; Breast cancer; Diagnosis code; Cancer; Demography; Internal medicine; Gynecology; Population","score_opus":0.09776540213586021,"score_gpt":0.49013002552391066,"score_spread":0.39236462338805045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410743176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5421535,0.041606262,0.00018773403,0.41385698,0.00062310667,0.0012026438,0.000007098804,0.00002384323,0.0003388742],"genre_scores_gemma":[0.72246814,0.027902937,0.000030410245,0.2490284,0.00014448167,0.0003556001,0.0000065222707,0.000009704788,0.00005382094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969489,0.0008607092,0.0006141294,0.00039049724,0.0004824059,0.0007033744],"domain_scores_gemma":[0.9913152,0.007904092,0.00015841628,0.0003434984,0.000028311815,0.0002504863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002786998,0.0002201169,0.00073033717,0.00027370476,0.00015867176,0.000011717281,0.00041340804,0.0002507494,0.00042307103],"category_scores_gemma":[0.002415194,0.00012356235,0.0000467526,0.0008481227,0.00050464104,0.00006898507,0.00006257846,0.0014268251,0.0000037555174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005094193,0.00029532032,0.7518406,0.0003532748,0.000015616946,0.00030033567,0.023325223,0.00015628767,0.0000036447186,0.00065682404,0.00009688044,0.22244658],"study_design_scores_gemma":[0.0031397294,0.0005710851,0.6024825,0.0005900518,0.000010993268,0.000043977154,0.0026978261,0.00014916624,0.0000033681738,0.0017992428,0.38841116,0.000100880294],"about_ca_topic_score_codex":0.060577072,"about_ca_topic_score_gemma":0.91556615,"teacher_disagreement_score":0.85498905,"about_ca_system_score_codex":0.0030271162,"about_ca_system_score_gemma":0.0095093725,"threshold_uncertainty_score":0.9961058},"labels":[],"label_agreement":null},{"id":"W4411680582","doi":"10.1177/17588359251351449","title":"Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Radioactivity and Radon Measurements","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"H2020 Euratom","keywords":"Radon; Lung cancer; Medicine; Radon exposure; Environmental health; Oncology","score_opus":0.06435925687664187,"score_gpt":0.45725076388737323,"score_spread":0.3928915070107314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411680582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814341,0.00726489,0.00072044245,0.002525261,0.00089966145,0.0014403524,0.0000040123123,0.000033091615,0.005678174],"genre_scores_gemma":[0.9929104,0.004488617,0.00045045125,0.0017833498,0.00005285667,0.00015911834,0.0000056354543,0.000018439709,0.00013116836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99398303,0.0035426952,0.0011549112,0.00042564442,0.00040766795,0.00048606037],"domain_scores_gemma":[0.99769133,0.0015320015,0.000253349,0.0002772504,0.00013500688,0.00011104396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024411273,0.00020835518,0.0007366105,0.00047729383,0.00013590301,0.0000032249666,0.00032929957,0.0003411071,0.00020353385],"category_scores_gemma":[0.0011068507,0.00017540592,0.000024257566,0.0014855713,0.0003412612,0.0002279734,0.00011792628,0.001499244,0.0000128718575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039381822,0.0018422086,0.8193734,0.00014567275,0.00004413948,0.00020405216,0.004787921,0.00006433357,0.0014544339,0.001773725,0.000022717852,0.16989356],"study_design_scores_gemma":[0.013798025,0.0011955256,0.96770823,0.0013498381,0.00005701656,0.000008243335,0.0025700438,0.0010435083,0.000067995745,0.002239947,0.00969063,0.00027098414],"about_ca_topic_score_codex":0.00028743802,"about_ca_topic_score_gemma":0.0070172176,"teacher_disagreement_score":0.16962259,"about_ca_system_score_codex":0.0003116045,"about_ca_system_score_gemma":0.0011840545,"threshold_uncertainty_score":0.7152846},"labels":[],"label_agreement":null},{"id":"W4412634163","doi":"10.1177/17588359251357719","title":"Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Dalhousie University; University of Calgary; Spinal Cord Injury BC; University of British Columbia; Princess Margaret Cancer Centre; BC Cancer Agency; Nova Scotia Health Authority; BC Cancer Foundation; Juravinski Cancer Centre","funders":"Eisai Canada; AstraZeneca Canada","keywords":"Medicine; Atezolizumab; Bevacizumab; Lenvatinib; Clinical endpoint; Oncology; Durvalumab; Internal medicine; Hepatocellular carcinoma; Embolization; Perioperative; Sorafenib; Clinical trial; Nivolumab; Surgery; Immunotherapy; Cancer; Chemotherapy","score_opus":0.041585286424058614,"score_gpt":0.3582130287363358,"score_spread":0.3166277423122772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412634163","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027017922,0.9879209,0.000058552312,0.00023794308,0.00020843536,0.0020443597,0.00001573142,0.000029280789,0.0067830444],"genre_scores_gemma":[0.07714983,0.921407,0.0002292523,0.00007742085,0.00007739181,0.0006050986,0.00018232985,0.000043646913,0.00022806552],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995883,0.0006974783,0.0017464017,0.0005963574,0.00053432316,0.0005424512],"domain_scores_gemma":[0.9975001,0.001308957,0.00041783156,0.00044201047,0.00011972384,0.0002113278],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00119219,0.00046566574,0.0032038814,0.0009870168,0.000057842422,0.000008824302,0.00029794103,0.0009465626,0.00027689597],"category_scores_gemma":[0.00047797227,0.00038046722,0.00030207183,0.0015206151,0.00040302303,0.00011800419,0.00019722007,0.00097108365,0.000007987905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012573187,0.0011991173,0.040819585,0.014352089,0.00013243538,0.00031913375,0.00022503769,4.100048e-7,0.00001350102,0.0019929977,0.0000057892757,0.9408142],"study_design_scores_gemma":[0.0064970683,0.001348972,0.0006093726,0.023100734,0.0010885483,0.0001736751,0.00024814619,0.0016697249,0.0002252629,0.004557315,0.96000165,0.00047955508],"about_ca_topic_score_codex":0.00021847131,"about_ca_topic_score_gemma":0.00018464404,"teacher_disagreement_score":0.95999587,"about_ca_system_score_codex":0.0005086076,"about_ca_system_score_gemma":0.002414222,"threshold_uncertainty_score":0.9998647},"labels":[],"label_agreement":null},{"id":"W4413427043","doi":"10.1177/17588359251361883","title":"The role of immunotherapy in resectable non-small-cell lung cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Immunotherapy; Lung cancer; Oncology; Cancer; Internal medicine","score_opus":0.01845210998458962,"score_gpt":0.4051781740363202,"score_spread":0.3867260640517306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413427043","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044302404,0.9849603,0.000060471786,0.00050951954,0.0009312448,0.0019363955,0.0000118763455,0.000019647718,0.011526238],"genre_scores_gemma":[0.000102571656,0.9965735,0.000104291874,0.0008278004,0.000190497,0.0010726731,0.000016662301,0.000053603453,0.0010583694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99582946,0.00066700455,0.0017146476,0.00052807096,0.00054973137,0.00071109534],"domain_scores_gemma":[0.99569076,0.0028548616,0.0006146308,0.00065896666,0.00007437291,0.00010639263],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019934627,0.0004802812,0.0028433218,0.00040879424,0.000078524194,0.000008790767,0.00088247954,0.00096165424,0.00055572554],"category_scores_gemma":[0.000114063456,0.00029537803,0.00048147404,0.0012568759,0.00065061526,0.00005605991,0.0001153305,0.001568742,0.0000036003428],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015152248,0.00037848085,0.0002909074,0.0075560277,0.00029191296,0.000051671068,0.00019626421,0.0000013439411,0.00001913222,0.00010777511,0.000050544077,0.9895407],"study_design_scores_gemma":[0.0038042315,0.00044927633,0.000032711323,0.026284961,0.00028879286,0.00003124112,0.0001923264,0.00007354904,0.000030211646,0.00035418212,0.96821713,0.00024136233],"about_ca_topic_score_codex":0.00038845552,"about_ca_topic_score_gemma":0.001542708,"teacher_disagreement_score":0.98929936,"about_ca_system_score_codex":0.0010851428,"about_ca_system_score_gemma":0.00595046,"threshold_uncertainty_score":0.9999498},"labels":[],"label_agreement":null},{"id":"W4414977427","doi":"10.1177/17588359251342241","title":"A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McGill University Health Centre","funders":"Daiichi Sankyo Europe; Genentech; Eisai; Natera; Seagen; Ipsen; Clovis Oncology; NRG Oncology; Incyte; Loxo Oncology; Toray Industries; Novocure; Regeneron Pharmaceuticals; Karyopharm Therapeutics; Mersana Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; PharmaMar; Celgene; Pfizer","keywords":"Placebo; Endometrial cancer; Plain language; Biomarker; English language; MEDLINE","score_opus":0.03257147208396524,"score_gpt":0.3963698474130543,"score_spread":0.3637983753290891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414977427","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028401185,0.98845434,0.00010945394,0.0002717014,0.0003876237,0.002554587,0.0002800561,0.000055460594,0.007602778],"genre_scores_gemma":[0.0010914331,0.99519515,0.00032627303,0.0003920774,0.00028930136,0.0010741921,0.0010925287,0.000060409413,0.00047862672],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99552333,0.0007192301,0.001251384,0.0007204998,0.0012145734,0.00057098735],"domain_scores_gemma":[0.9945131,0.0036062002,0.0008143436,0.00048078617,0.0002775908,0.0003079877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006290396,0.0006084588,0.004161331,0.0009068753,0.000044168086,0.000008626208,0.00038522188,0.0006946011,0.0007889442],"category_scores_gemma":[0.0007814268,0.00034547408,0.00026294848,0.002967299,0.0004863433,0.00011770928,0.000090941656,0.00095364853,0.000004684249],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006779375,0.0010240538,0.0017809991,0.007266002,0.000845187,0.00017022862,0.000106476065,0.0000012836348,1.4972137e-7,0.00013344202,0.000016811959,0.981876],"study_design_scores_gemma":[0.039935347,0.0069710966,0.000377713,0.017338995,0.0037827773,0.000030451038,0.0001649973,0.000009418877,0.0000054992656,0.000034784647,0.9308546,0.00049427804],"about_ca_topic_score_codex":0.00054225815,"about_ca_topic_score_gemma":0.0011760518,"teacher_disagreement_score":0.9813817,"about_ca_system_score_codex":0.0016300413,"about_ca_system_score_gemma":0.0040510213,"threshold_uncertainty_score":0.99989974},"labels":[],"label_agreement":null},{"id":"W4415229284","doi":"10.1177/17588359251385393","title":"Orthopedic interventions and outcomes in patients with metastatic renal cell carcinoma: a systematic review","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; London Health Sciences Centre; Western University","funders":"","keywords":"Orthopedic surgery; Quality of life (healthcare); Multidisciplinary approach; Psychological intervention; Narrative review; MEDLINE; Retrospective cohort study; Systemic therapy","score_opus":0.03306252715342925,"score_gpt":0.41246896238881975,"score_spread":0.3794064352353905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415229284","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021783644,0.9902478,0.00047034334,0.00043254928,0.00016013136,0.0076520066,0.000024795496,0.00002564747,0.00096493925],"genre_scores_gemma":[0.00017916171,0.9938621,0.0007230883,0.0026165838,0.000012273941,0.0017390657,0.00015392821,0.000042569078,0.0006712379],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99376744,0.0017705071,0.002390975,0.00065209024,0.0009493421,0.0004696458],"domain_scores_gemma":[0.996257,0.0018790455,0.0008631736,0.0006240184,0.00007784776,0.00029888932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020362942,0.0005907695,0.0067775454,0.00071869325,0.00003078766,0.000008571839,0.00037350116,0.0002020934,0.0003802566],"category_scores_gemma":[0.0013393054,0.0003570362,0.0004494327,0.000809606,0.00030749262,0.0001061295,0.0001938418,0.0009444566,0.000017512748],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047115383,0.0011684276,0.0008374681,0.6852183,0.0001936283,0.00036571527,0.000019250747,6.0273464e-8,2.2601523e-10,0.00008509709,0.000018653991,0.3120463],"study_design_scores_gemma":[0.00627822,0.001237223,0.00055312004,0.8752368,0.02094083,0.000033327346,0.00006340762,0.000007784211,3.0502434e-9,0.00012049663,0.095159866,0.00036893177],"about_ca_topic_score_codex":0.000005865866,"about_ca_topic_score_gemma":0.000066906505,"teacher_disagreement_score":0.31167734,"about_ca_system_score_codex":0.00036261504,"about_ca_system_score_gemma":0.0010703128,"threshold_uncertainty_score":0.9998882},"labels":[],"label_agreement":null},{"id":"W4415459306","doi":"10.1177/17588359251367315","title":"A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Nivolumab; Retrospective cohort study; Myeloid; Immune system; Immunotherapy; Programmed cell death 1","score_opus":0.008752935889310028,"score_gpt":0.29337686642125704,"score_spread":0.284623930531947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415459306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920008,0.0051159253,0.00028067178,0.0012818665,0.00011614923,0.0010108241,0.000009415887,0.000015132126,0.00016917278],"genre_scores_gemma":[0.9961684,0.0020558964,0.0008987304,0.00046633612,0.000012602639,0.00036247273,0.00000851613,0.000009580365,0.000017496288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981344,0.00030019484,0.00054404995,0.0003271632,0.00045299355,0.00024124219],"domain_scores_gemma":[0.99878407,0.0005672357,0.00022623254,0.00021038552,0.00012134058,0.000090730064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070743734,0.00018301686,0.0008023715,0.00036303623,0.000049501723,0.0000062348,0.00009203355,0.00009706245,0.000021027208],"category_scores_gemma":[0.00049452716,0.00011434635,0.00007142393,0.0008346834,0.00024799886,0.00014418048,0.00009588348,0.0002017732,4.2997158e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002566192,0.00046873293,0.8620272,0.000058715737,0.000989011,0.000021652975,0.00059916533,0.000027116108,0.00005482102,0.00022658042,4.1846235e-7,0.1329604],"study_design_scores_gemma":[0.0075222556,0.0009559201,0.9886565,0.00020704082,0.0009122309,8.491842e-7,0.0003256961,0.00022079438,0.000665331,0.00018593924,0.00025121888,0.00009620644],"about_ca_topic_score_codex":0.000023199935,"about_ca_topic_score_gemma":0.0002258084,"teacher_disagreement_score":0.13286419,"about_ca_system_score_codex":0.00094600726,"about_ca_system_score_gemma":0.00019637414,"threshold_uncertainty_score":0.4662909},"labels":[],"label_agreement":null},{"id":"W4415651750","doi":"10.1177/17588359251386765","title":"Prognostic utility of inflammatory indices and circulating nucleic acids for neoadjuvant chemotherapy outcomes in breast cancer: a systematic review","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemotherapy; Nucleic acid; MEDLINE; Breast cancer; Value (mathematics); Circulating tumor DNA","score_opus":0.024086511766256227,"score_gpt":0.40564639681080533,"score_spread":0.38155988504454913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415651750","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026679435,0.9872953,0.000056186123,0.0008804876,0.0003048237,0.010925003,0.00008592919,0.000053770946,0.00013167706],"genre_scores_gemma":[0.00091315486,0.9911403,0.00035873652,0.0017166198,0.00006591371,0.005692769,0.000035362667,0.00006479226,0.000012348919],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99350053,0.0011122174,0.0032637983,0.00078428705,0.00071376475,0.0006254255],"domain_scores_gemma":[0.9928672,0.0045447834,0.0015665095,0.0006084031,0.00015750312,0.00025560506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031944835,0.0007065678,0.008089032,0.0005717749,0.000051763,0.000008008071,0.0005569338,0.0008921771,0.00017708662],"category_scores_gemma":[0.0019604675,0.000506316,0.00056879316,0.0007337972,0.00074813486,0.00012386493,0.00015742033,0.00084281847,0.0000016420546],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009745974,0.00023034873,0.01742798,0.5155639,0.00035458757,0.000057447105,0.00006169597,3.6470045e-8,9.925294e-8,0.00003798359,0.0000037245359,0.4661647],"study_design_scores_gemma":[0.002957185,0.0002004739,0.0038356506,0.95343083,0.00519856,0.00023767425,0.000090501104,0.00015702525,3.47971e-7,0.0003145953,0.033128217,0.00044895496],"about_ca_topic_score_codex":0.0000080619475,"about_ca_topic_score_gemma":0.00004074407,"teacher_disagreement_score":0.46571577,"about_ca_system_score_codex":0.0005183815,"about_ca_system_score_gemma":0.002932964,"threshold_uncertainty_score":0.9997389},"labels":[],"label_agreement":null},{"id":"W4415733338","doi":"10.1177/17588359251387393","title":"Antibody–drug conjugates versus docetaxel for previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Docetaxel; Randomized controlled trial; Overall survival; Lung; Lung cancer; Subgroup analysis; Clinical trial","score_opus":0.055942934672215214,"score_gpt":0.5015752000993928,"score_spread":0.4456322654271776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415733338","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000014914095,0.949631,0.0013006815,0.0007457958,0.00027372254,0.047058184,0.00026501121,0.000032593784,0.00069155294],"genre_scores_gemma":[0.000026847409,0.9546282,0.0006079012,0.0010432989,0.00004115477,0.041808866,0.0005624666,0.000046520327,0.0012347422],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9869496,0.004784275,0.006392715,0.0008219756,0.0005500673,0.00050135714],"domain_scores_gemma":[0.9489049,0.044937633,0.0048694876,0.00061767147,0.0004151051,0.000255241],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.009872596,0.0009148201,0.08222096,0.00085876806,0.00006938723,0.000013307501,0.00036612415,0.00048762903,0.0004755913],"category_scores_gemma":[0.0072746384,0.00045199096,0.008807047,0.0012479352,0.0003996525,0.00007546073,0.000058664733,0.00045169747,9.554967e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013143885,0.0003328979,8.829272e-7,0.57395494,0.38005397,0.000020026719,0.0001107643,0.0000053262243,1.8149294e-7,0.00009925977,0.000008394162,0.032269496],"study_design_scores_gemma":[0.17614855,0.00028337288,3.823416e-8,0.07705599,0.7319925,0.0000063705174,0.00004001245,0.00018993419,5.3859077e-7,0.000030395784,0.014025902,0.00022642942],"about_ca_topic_score_codex":0.000055488148,"about_ca_topic_score_gemma":0.00013812628,"teacher_disagreement_score":0.49689892,"about_ca_system_score_codex":0.00047992542,"about_ca_system_score_gemma":0.002984886,"threshold_uncertainty_score":0.9997932},"labels":[],"label_agreement":null},{"id":"W4416554337","doi":"10.1177/17588359251339939","title":"Characteristics of <i>KRAS</i> WT pancreatic adenocarcinomas: results of a large French multicentric cohort","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cohort; Targeted therapy; Mutation; Gene; Pancreatic cancer; Cohort study; MEDLINE","score_opus":0.005081101432230146,"score_gpt":0.3071218625817954,"score_spread":0.30204076114956524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416554337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9112115,0.065536685,0.005243953,0.0012339614,0.0010636158,0.0006010605,0.000079911755,0.0000151713775,0.015014151],"genre_scores_gemma":[0.9640973,0.034398954,0.000236566,0.00082694856,0.00007243277,0.000027331887,0.00006080427,0.00000868379,0.0002709386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982499,0.00020089946,0.0007237781,0.00029336847,0.00023911525,0.00029293945],"domain_scores_gemma":[0.99909216,0.00019171841,0.00027890896,0.0002684032,0.00009206841,0.000076751516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055909524,0.00014535754,0.0005083837,0.000095925134,0.00002348976,0.0000014066827,0.0003116736,0.0004006466,0.000044195956],"category_scores_gemma":[0.00036635302,0.00011448525,0.00008296295,0.0003001837,0.00049398834,0.0000044445205,0.00009500955,0.00025873625,0.0000017817953],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004423256,0.0022841713,0.27911508,0.0009369673,0.00094867824,0.0001242761,0.00058385317,0.0001279347,0.039479267,0.0022666114,0.0008773816,0.66883254],"study_design_scores_gemma":[0.020157292,0.0034994055,0.21102388,0.0011315194,0.00061414915,0.000060188955,0.00058792986,0.001608394,0.06660614,0.001753946,0.6922671,0.0006899971],"about_ca_topic_score_codex":0.000043234864,"about_ca_topic_score_gemma":0.00005385344,"teacher_disagreement_score":0.69138974,"about_ca_system_score_codex":0.000051670882,"about_ca_system_score_gemma":0.00043108696,"threshold_uncertainty_score":0.46685728},"labels":[],"label_agreement":null},{"id":"W7116844250","doi":"10.1177/17588359251385410","title":"TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with <i>EGFR</i> -mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"Daiichi Sankyo Europe; National Cancer Institute; Eli Lilly Japan; Pfizer Japan; EMD Serono; Daiichi-Sankyo; Eli Lilly and Company; Ono Pharmaceutical; Sanofi; Apollomics; Yuhan; Taiho Pharmaceutical; Boehringer Ingelheim Japan; BeiGene; Chugai Pharmaceutical; Nihon Medi-Physics; Astellas Pharma; AstraZeneca; Novocure; Genomic Health; GlaxoSmithKline; Amgen; Pfizer; Les Laboratories Pierre Fabre; Bristol-Myers Squibb","keywords":"Osimertinib; Lung cancer; Chemotherapy; Disease; Randomized controlled trial; Phases of clinical research; Clinical trial; Lung disease","score_opus":0.012525595294375842,"score_gpt":0.3687785906845456,"score_spread":0.35625299539016975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116844250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832274,0.0038063014,0.00047069506,0.002265842,0.00026569614,0.009619294,0.0000406595,0.000063085456,0.00024107058],"genre_scores_gemma":[0.993389,0.001427055,0.0008478981,0.0014177539,0.000030449415,0.0025206064,0.00018237959,0.00006853649,0.000116334886],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99622595,0.00038379466,0.0011642124,0.0008942178,0.0007143797,0.0006174349],"domain_scores_gemma":[0.9970844,0.0011800881,0.00059162424,0.0005477243,0.00020876038,0.00038742364],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038566033,0.00056880375,0.002041032,0.00034004214,0.00014692213,0.000020766423,0.00028654502,0.00018673991,0.00017491539],"category_scores_gemma":[0.00013206048,0.0003490441,0.00007180706,0.00091515086,0.0007590257,0.00019870233,0.000068867645,0.0005567907,8.2308094e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75386465,0.018611448,0.048356835,0.00032768576,0.0011362841,0.00031138194,0.003116145,0.00017608733,0.000036287314,0.000023304336,0.000015867357,0.17402405],"study_design_scores_gemma":[0.95850927,0.019907001,0.011015511,0.0016043815,0.002026305,0.000003200504,0.0014353523,0.00287384,0.00041899175,0.000032561733,0.0017557709,0.00041781517],"about_ca_topic_score_codex":0.00016076097,"about_ca_topic_score_gemma":0.0010907096,"teacher_disagreement_score":0.20464464,"about_ca_system_score_codex":0.00048254617,"about_ca_system_score_gemma":0.0023068148,"threshold_uncertainty_score":0.99989617},"labels":[],"label_agreement":null}]}